

GRANTS AND BURSARIES							
APRIL 1, 2011 - MARCH 31, 2012							
NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
		<b>JGH Totals (External grants &amp; career awards)</b>	<b>38,329,515</b>		<b>5,602,948</b>		<b>7,331,612</b>
		<b>Medicine Totals (External grants &amp; career awards)</b>	<b>26,298,065</b>				
		<b>Medicine - Totals</b>	<b>23,906,008</b>	<b>2,392,057</b>	<b>4,996,075</b>	<b>168,000</b>	<b>1,300,350</b>
<a href="#">Alaoui-Jamali, Moulay</a>	<a href="#">Université McGill</a>	<a href="#">Study of the function of Rab-GTPase in breast cancer.</a>		<a href="#">2,421</a>			
<a href="#">Alaoui-Jamali, Moulay</a>	<a href="#">Université McGill</a>	<a href="#">Study of the function of Rab-GTPase in breast cancer.</a>		<a href="#">2,721</a>			
<a href="#">Alaoui-Jamali, Moulay</a>	<a href="#">Institut National du Cancer du Canada</a>	<a href="#">Mechanism of gap junction downregulation in mammary tumor cells and potential therapeutic implications in breast cancer.</a>	<a href="#">11,620</a>				
<a href="#">Alaoui-Jamali, Moulay</a>	<a href="#">Société Canadienne du Cancer</a>		<a href="#">31,525</a>				
<a href="#">Alaoui-Jamali, Moulay</a>	<a href="#">Fondation du Cancer du Sein du Québec</a>		<a href="#">37,500</a>				
<a href="#">Alaoui-Jamali, Moulay</a>	<a href="#">Fondation du Cancer du Sein du Québec</a>		<a href="#">75,000</a>				
<a href="#">Alaoui-Jamali, Moulay</a>	<a href="#">Société Canadienne du Cancer</a>		<a href="#">96,062</a>				
<a href="#">Alaoui-Jamali, Moulay</a>	<a href="#">Instituts de Recherche en Santé du Canada</a>		<a href="#">133,514</a>				
<a href="#">Alaoui-Jamali, Moulay</a>	<a href="#">Instituts de Recherche en Santé du Canada</a>	<a href="#">Investigation of the filamin signaling network's function in cancer progression.</a>	<a href="#">156,832</a>				
<a href="#">Aloyz, Raquel Silvia</a>	<a href="#">Leukemia &amp; Lymphoma Society of Canada</a>	<a href="#">Mechanisms of Dasatinib mediated cytotoxicity in CLL cells.</a>		<a href="#">3,500</a>			
<a href="#">Aloyz, Raquel Silvia</a>	<a href="#">Leukemia and Lymphoma Society</a>	<a href="#">Assessment of a telomerase inhibitor in chronic lymphocytic leukemia (CIL).</a>	<a href="#">63,985</a>				
<a href="#">Aloyz, Raquel Silvia</a>	<a href="#">Leukemia and Lymphoma Society</a>	<a href="#">Assessment of a telomerase inhibitor in chronic lymphocytic leukemia (CIL).</a>	<a href="#">64,160</a>				
<a href="#">Aloyz, Raquel Silvia</a>	<a href="#">Instituts de Recherche en Santé du Canada</a>	<a href="#">Mechanisms of dasatinib cytotoxicity and sensitization therapy in chronic lymphocytic leukemia.</a>	<a href="#">92,194</a>				
<a href="#">Assouline, Sarit</a>	<a href="#">Fonds de la Recherche en Santé du Québec</a>			<a href="#">8,334</a>			
<a href="#">Assouline, Sarit</a>	<a href="#">Fonds de la Recherche en Santé du Québec</a>			<a href="#">26,089</a>			
<a href="#">Assouline, Sarit</a>	<a href="#">Fonds de la Recherche en Santé du Québec</a>		<a href="#">2,473</a>				
<a href="#">Assouline, Sarit</a>	<a href="#">Fonds de la Recherche en Santé du Québec</a>		<a href="#">7,534</a>				
<a href="#">Autexier, Chantal</a>	<a href="#">Université McGill</a>	<a href="#">Telomerase structure and function.</a>		<a href="#">859</a>			
<a href="#">Autexier, Chantal</a>	<a href="#">Université McGill</a>	<a href="#">Ph.D. Program in Experimental Medicine / A McGill CIHR Drug Development Training Program Scholarship.</a>		<a href="#">1,462</a>			
<a href="#">Autexier, Chantal</a>	<a href="#">Université McGill</a>	<a href="#">Faculty of Medicine Internal Studentship Awards - Ruth and Alex Dworkin Fellowship.</a>		<a href="#">4,176</a>			
<a href="#">Autexier, Chantal</a>	<a href="#">Fonds de la Recherche en Santé du Québec</a>	<a href="#">Mécanismes impliqués dans la sensibilisation de cellules cancéreuses à des agents chimiothérapeutiques par l'expression d'un composant ARN mutant de la télomérase</a>		<a href="#">4,945</a>			
<a href="#">Autexier, Chantal</a>	<a href="#">Université McGill</a>	<a href="#">Ph.D. Program in Experimental Medicine / A McGill CIHR Drug Development Training Program Scholarship.</a>		<a href="#">7,527</a>			
<a href="#">Autexier, Chantal</a>	<a href="#">Fonds de la Recherche en Santé du Québec</a>	<a href="#">Structure, fonction et régulation de la télomérase: éléments clés contrôlant la prolifération et le vieillissement cellulaire</a>		<a href="#">17,765</a>			
<a href="#">Autexier, Chantal</a>	<a href="#">Fonds de la Recherche en Santé du Québec</a>	<a href="#">Structure, fonction et régulation de la télomérase: éléments clés contrôlant la prolifération et le vieillissement cellulaire</a>		<a href="#">32,277</a>			
<a href="#">Autexier, Chantal</a>	<a href="#">Instituts de Recherche en Santé du Canada</a>	<a href="#">Investigation of telomere and telomerase regulation by associated proteins and in primary malignant lymphocytes.</a>		<a href="#">32,430</a>			
<a href="#">Autexier, Chantal</a>	<a href="#">Instituts de Recherche en Santé du Canada</a>	<a href="#">Supramolecular complexes as G-quadruplex binders: Towards effective telomerase inhibition.</a>	<a href="#">17,277</a>				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Autexier, Chantal	Institut de Recherche de la Société Canadienne du Cancer		31,414				
Autexier, Chantal	Institut de Recherche de la Société Canadienne du Cancer		95,724				
Autexier, Chantal	Instituts de Recherche en Santé du Canada	Telomerase structure and function.	121,604				
Baron, Murray	Conseil de Recherches en Sciences Naturelles et Génie du Canada	Alexander Graham Bell Canada Graduate Scholarship.		35,000			
Baron, Murray	Fonds de la Recherche en Santé du Québec	Développement et validation d'un système intégré pour évaluer la fatigue liée à la sclérodémie	1,069				
Baron, Murray	Instituts de Recherche en Santé du Canada	A new emerging team: The Canadian scleroderma research group.	9,424				
Baron, Murray	Instituts de Recherche en Santé du Canada	Meeting of the Canadian Consortium of Rheumatology Cohorts (CANCoRC)	16,758				
Baron, Murray	Instituts de Recherche en Santé du Canada	Meeting of the Canadian Consortium of Rheumatology Cohorts (CANCoRC)	20,133				
Baron, Murray	Regroupement de Particuliers		93,278				
Baron, Murray	Instituts de Recherche en Santé du Canada	Strategic training initiative - Canadian Scleroderma Research Group.	151,500				
Batist, Gerald	Friedrich Ebert Stiftung	Cu3 and ahr interaction in chemoresistance.		539			
Batist, Gerald	Université McGill	Studies in anti-cancer therapeutics resistance.		1,170			
Batist, Gerald	Instituts de Recherche en Santé du Canada	Phase 2 trial of aminoflavone for breast cancer.		2,834			
Batist, Gerald	Université McGill	Hematobiliary surgery.		12,603			
Batist, Gerald	Regroupement de Particuliers	Imaging facility.	1,955				
Batist, Gerald	Fonds de la Recherche en Santé du Québec		3,163				
Batist, Gerald	Regroupement de Particuliers	Oncology Research	4,017				
Batist, Gerald	Regroupement de Particuliers	Imaging facility.	4,667				
Batist, Gerald	Regroupement de Particuliers	Research pathology facility.	4,780				
Batist, Gerald	Instituts de Recherche en Santé du Canada		5,531				
Batist, Gerald	Instituts de Recherche en Santé du Canada	2nd Québec Conference on Therapeutic Resistance in Cancer	8,750				
Batist, Gerald	Fonds de la Recherche en Santé du Québec	Étude prospective pour identifier et valider des biomarqueurs de résistance thérapeutique dans le cancer colorectal métastatique	17,666				
Batist, Gerald	Princess Margaret Hospital Foundation	Ride 2009 Royalty collaborative research.	46,000				
Batist, Gerald	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	A randomized phase III study of standard treatment +/- enoxaparin in small cell lung cancer, RASTEN study Canadian part.	70,000				
Batist, Gerald	Fonds de la Recherche en Santé du Québec	Étude prospective pour identifier et valider des biomarqueurs de résistance thérapeutique dans le cancer colorectal métastatique	71,450				
Batist, Gerald	Amgen Canada Inc (Mississauga, Ont)	Colorectal Cancer New Treatments (AMG).	238,771				
Batist, Gerald	Regroupement de Particuliers	Translational Research Center.	245,136				
Beitel, Lenore	Réseau des Centres D'excellence Fédéral	Opto-Impedimetric Screening of Blood-borne Pathogens.	6,233				
Beitel, Lenore	Réseau des Centres D'excellence Fédéral	Opto-Impedimetric Screening of Blood-borne Pathogens.	18,819				
Beland, François	Instituts de Recherche en Santé du Canada	Qualité des soins lors des transitions des personnes âgées atteintes de maladies chroniques: une analyse des injections et des pratiques de gestion cliniques.		13,611			
Beland, François	Instituts de Recherche en Santé du Canada		2,257				
Beland, François	Instituts de Recherche en Santé du Canada		3,656				
Beland, François	Ministère de la Santé et des Services Sociaux (Québec)		26,556				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Beland, François	Ministère de la Santé et des Services Sociaux (Québec)	FRELE: Fragilité, une étude longitudinale de ses expressions et accés, utilisation et couts des services sociaux et de sante associes aux profils et trajectoires de fragilite.	92,320				
Beland, François	Instituts de Recherche en Santé du Canada	CIHR Team in frailty and aging	105,628				
Bergman, Howard	Fonds de la Recherche en Santé du Québec	Le processus décisionnel concernant les choix de traitement chez les personnes âgées atteintes d'un cancer colorectal		10,998			
Bergman, Howard	Instituts de Recherche en Santé du Canada		11,850				
Bergman, Howard	Ministère de la Santé et des Services Sociaux (Québec)	FRELE: Fragilité, une étude longitudinale de ses expressions et accés, utilisation et couts des services sociaux et de sante associes aux profils et trajectoires de fragilite.	15,388				
Bergman, Howard	Instituts de Recherche en Santé du Canada	CIHR Team in frailty and aging	30,368				
Bergman, Howard	Acker Finley Inc.	Ronald Oberlander Fellow.	116,679				
Bergman, Howard	Instituts de Recherche en Santé du Canada		286,837				
Billick, Robin	Regroupement de Particuliers	Dermatology Research.	4,641				
Blank, Volker	Université McGill	Cytokine-induced expression of mafF transcription factor in myometrial cells.		1,130			
Blank, Volker	Instituts de Recherche en Santé du Canada	Analysis of novel regulators of erythroid differentiation.		1,750			
Blank, Volker	Université McGill	Role of the MafF transcription factor in uterine and breast cancer cells.		2,000			
Blank, Volker	Université McGill	Role of Nrf3 transcription factor in carcinogenesis.		2,635			
Blank, Volker	Université McGill	The role of CNC transcription factors in carcinogenesis.		6,000			
Blank, Volker	Université McGill	Role of Nrf3 transcription factor in carcinogenesis.		9,033			
Blank, Volker	Conseil de Recherches en Sciences Naturelles et Génie du Canada	Regulators mediating the proinflammatory cytokine response in uterine smooth muscle cells.	25,000				
Blank, Volker	Fondation du Cancer du Sein du Québec	Contrôle de l'invasion de cellules de sein cancéreuses par des facteurs de transcription de type CNC.	29,610				
Blank, Volker	Instituts de Recherche en Santé du Canada		99,413				
Blostein, Mark	Instituts de Recherche en Santé du Canada	Pharmacogenomic Study of Warfarin.	2,100				
Blostein, Mark	Fondation des Maladies du Coeur du Québec	Role of gas6 in vascular biology.	4,945				
Blostein, Mark	Fondation des Maladies du Coeur du Québec	Role of gas6 in vascular biology.	12,055				
Blostein, Mark	Instituts de Recherche en Santé du Canada	A double-blind, randomized control trial of post-operative low molecular weight heparin bridging therapy versus placebo bridging therapy for patients who are at high risk for arterial thromboembolism.	15,053				
Blostein, Mark	Instituts de Recherche en Santé du Canada	Role of Gas6 in Vascular Biology	126,395				
Blostein, Mark	National Institutes of Health	U01HL087229 - Bridging anticoagulation in patients who Require temporary Interruption of warfarin therapy for an elective invasive proceDure or surGEry(BRIDGE) trial.	2,382,886				
Cen, Shan	Université McGill	Mechanisms of how vif efficiently protects HIV-1 from the attack of hA3G. The potential of APOBEC3G in the development of a novel anti-HIV-1 therapeutic.		5,011			
Cen, Shan	Instituts de Recherche en Santé du Canada	The potential of APOBEC3G in the development of a novel anti-HIV-1 therapeutic.	81,998				
Chalifour, Lorraine	Conseil de Recherches en Sciences Naturelles et Génie du Canada	Hemovascular Research.		4,500			

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Chalifour, Lorraine	Fondation des Maladies du Coeur du Québec	Endocrine disruptor re-programming of the heart: mechanism and implications for the progression to disease.	18,836				
Chalifour, Lorraine	Conseil de Recherches en Sciences Naturelles et Génie du Canada		35,000				
Chalifour, Lorraine	Instituts de Recherche en Santé du Canada	Steroid hormone programming in heart.	111,509				
Chertkow, Howard	Université de Montréal	Pilot project: characterizing atypical dementias with multi-modal neuroimaging.	9,000				
Chertkow, Howard	Instituts de Recherche en Santé du Canada	Alzheimer's disease cooperative study - project #1.	27,001				
Chertkow, Howard	Instituts de Recherche en Santé du Canada	Anomia in Alzheimer's Disease: Untangling semantic components and delivering therapy with rTMS.	27,595				
Chertkow, Howard	National Institutes of Health	A randomized, double-blind, placebo-controlled, two dose-arm, parallel study of the safety and effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the treatment of mild-to moderate Alzheimer's Disease.	34,255				
Chertkow, Howard	Instituts de Recherche en Santé du Canada	Create the Canadian dementia knowledge translation network (CDKTN).	35,006				
Chertkow, Howard	National Institutes of Health	Clinical assessment of patients with AD and NEC individuals.	53,382				
Chertkow, Howard	Instituts de Recherche en Santé du Canada	Diagnosis, localization, and treatment of semantic memory impairment in Alzheimer's Disease.	74,921				
Chertkow, Howard	Instituts de Recherche en Santé du Canada	Establishing prognostic subgroups in mild cognitive impairment.	126,503				
Chertkow, Howard	Regroupement de Particuliers	Bronfman Foundation.	550,739				
Chong, George	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	High sensitivity blood test for early detection of colorectal cancer.	36,822				
Chong, George	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Fast-tracking genetic testing for BRCA1 and BRCA2 in selected Montreal populations.	40,000				
Cohen, Albert	Regroupement de Particuliers	Inflammatory bowel disease.	23,279				
Cohen, Albert	Merck Frosst Canada Inc	IBD educational fund.	25,507				
Cohen, Albert	Regroupement de Particuliers	Gastroenterology Research.	33,947				
Cohen, Albert	Janssen-Ortho Inc.	Fellowship - IBD training.	50,000				
Cohen, S Robin	Instituts de Recherche en Santé du Canada			24,730			
Cohen, S Robin	Fondation Canadienne du Rein		1,236				
Cohen, S Robin	Max Bell Foundation		22,475				
Dascal, André	Regroupement de Particuliers	Microbiology Research.	966				
De Marchie, Michel	Ontario Neurotrauma Foundation		917				
Eisenberg, Mark	Université McGill	Patient Empowerment Newsletter.		800			
Eisenberg, Mark	Université McGill	Comparing the safety and efficacy of new oral anticoagulants versus warfarin for patients with atrial fibrillation: a systematic review and meta-analysis.		2,384			
Eisenberg, Mark	Université McGill	A systematic review of the cardiovascular and vascular risk related to combined oral contraceptives.		3,333			
Eisenberg, Mark	Fonds de la Recherche en Santé du Québec	Prévention Secondaire Chez Les Patients Ayant Subi Un Syndrome Coronaire Aigu		7,418			
Eisenberg, Mark	Fonds de la Recherche en Santé du Québec	Prévention Secondaire Chez Les Patients Ayant Subi Un Syndrome Coronaire Aigu		22,603			
Eisenberg, Mark	Instituts de Recherche en Santé du Canada	The safety of combined oral contraceptives: a systematic review and meta-analysis.	1,890				
Eisenberg, Mark	Fondation des Maladies du Coeur du Québec	The efficacy of weight loss interventions: a systematic review and hierarchical Bayesian meta-analysis.	4,945				
Eisenberg, Mark	Instituts de Recherche en Santé du Canada	Unconventional Smoking Cessation Aids: A Meta-Analysis of Randomized Controlled Trials.	53,626				
Eliopoulos, Nicoletta	Génome Québec	Cell therapy of cystinosis	27,403				
Eliopoulos, Nicoletta	Génome Québec	Cell therapy of cystinosis	32,679				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Eliopoulos, Nicoletta	Instituts de Recherche en Santé du Canada	A study of novel anti-cancer immunomodulatory fusion proteins and transgenic cell therapy.	229,515				
Ernst, Pierre-Paul	Instituts de Recherche en Santé du Canada	CIHR - Quebec Respiratory Health Training Program	8,125				
Ernst, Pierre-Paul	Instituts de Recherche en Santé du Canada		10,000				
Ernst, Pierre-Paul	Richard and Edith Strauss Canadian Foundation	Difficult-to-treat asthma	10,584				
Filion, Kristian	Instituts de Recherche en Santé du Canada	The cardiovascular safety of varenicline: A population-based cohort study.	14,231				
Foulkes, William David	Fonds de la Recherche en Santé du Québec	Progression de la caractérisation des cancers héréditaires du sein, colorectal et de la prostate au Québec.		3,709			
Foulkes, William David	Université McGill	Correcting the mismatch repair gene PMS2 as a model for disase therapy.		7,527			
Foulkes, William David	Ministère du Développement Economique, de l'innovation et de l'exportation (MDEIE)	Séquençage de nouvelle génération en génétique moléculaire pour le cancer du sein héréditaire - une nouvelle stratégie émergente	678				
Foulkes, William David	Ministère du Développement Economique, de l'innovation et de l'exportation (MDEIE)	Séquençage de nouvelle génération en génétique moléculaire pour le cancer du sein héréditaire - une nouvelle stratégie émergente	1,517				
Foulkes, William David	Ministère du Développement Economique, de l'innovation et de l'exportation (MDEIE)	Séquençage de nouvelle génération en génétique moléculaire pour le cancer du sein héréditaire - une nouvelle stratégie émergente	1,517				
Foulkes, William David	Fondation du Cancer du Sein du Québec		2,188				
Foulkes, William David	Ministère du Développement Economique, de l'innovation et de l'exportation (MDEIE)	Séquençage de nouvelle génération en génétique moléculaire pour le cancer du sein héréditaire - une nouvelle stratégie émergente	2,758				
Foulkes, William David	Fondation du Cancer du Sein du Québec		3,154				
Foulkes, William David	Alliance Canadienne Pour La Recherche sur Le Cancer du Sein		4,604				
Foulkes, William David	Instituts de Recherche en Santé du Canada		4,978				
Foulkes, William David	Mendon F. Schutt Family Fund	Screening DICER-like families for large deletions in DICER1 or for mutations or deletions of DICER1-like genes.	5,686				
Foulkes, William David	Ministère du Développement Economique, de l'innovation et de l'exportation (MDEIE)	Séquençage de nouvelle génération en génétique moléculaire pour le cancer du sein héréditaire - une nouvelle stratégie émergente	6,267				
Foulkes, William David	Fondation du Cancer du Sein du Québec		6,563				
Foulkes, William David	National Institutes of Health	PROSTATE CANCER SUSCEPTIBILITY: THE ICPCG STUDY	7,919				
Foulkes, William David	Institute of Cancer Research (Icr) (Uk)	IMPACT - Identification of Men with a Genetic predisposition to ProstAte Cancer: Targeted screening in BRCA 1/2 mutation carriers and controls.	11,518				
Foulkes, William David	Société Canadienne du Cancer	Correcting splicing in the mismatch repair gene PMS2 as a model for therapy of genetic diseases.	12,363				
Foulkes, William David	Alliance Canadienne Pour La Recherche sur Le Cancer du Sein		14,028				
Foulkes, William David	Société de Recherche sur Le Cancer Inc	Dissemination of the creativity and prevention of mental health problems in multiethnic schools	17,507				
Foulkes, William David	Société de Recherche sur Le Cancer Inc	A multimodal genomic analysis strategy to identify novel breast cancer genes.	17,507				
Foulkes, William David	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Establishing a Quebec hereditary colorectal cancer registry.	34,521				
Foulkes, William David	Susan G. Komen Breast Cancer Foundation	hereditary Breat Cancer: Cause and Effect.	41,619				
Foulkes, William David	Régrouperment de Particuliers	Surgical Research.	46,777				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Foulkes, William David	Mendon F. Schutt Family Fund	Mutations of DICER1 and miRNA dysregulation as causes of childhood and young adult disease.	50,080				
Foulkes, William David	Susan G. Komen Breast Cancer Foundation	Systematic characterization of dasatinib sensitivity and resistance in BrCa cells.	59,163				
Galiatsatos, Polymnia	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Accuracy of biopsies for Helicobacter Pylori in the presence of intestinal metaplasia of the stomach.	4,603				
Gatignol, Anne	Université McGill	M.Sc. Program in Experimental Medicine		835			
Gatignol, Anne	Université McGill	Control of the regulation of PKR activity during HIV infection.		5,836			
Gatignol, Anne	Instituts de Recherche en Santé du Canada			24,730			
Gatignol, Anne	Instituts de Recherche en Santé du Canada	Characterization and modulation of the immune activation during HIV infection.		35,000			
Gatignol, Anne	Instituts de Recherche en Santé du Canada	Regulation of HIV-1 replication by RNA interference and proteins of the RISC.		50,000			
Gatignol, Anne	Instituts de Recherche en Santé du Canada	Exploring interactions between HIV and the RNA interference pathway.	92,667				
Gatignol, Anne	Instituts de Recherche en Santé du Canada	Virus-cell interactions in the regulation of HIV translation.	123,042				
Greenaway, Christina	Fonds de la Recherche en Santé du Québec	Détermination de la stratégie optimale pour réduire le fardeau associé à l'hépatite B chez les immigrants et les réfugiés au Canada: une analyse de coût-efficacité		7,500			
Greenaway, Christina	Fonds de la Recherche en Santé du Québec	Les maladies infectieuses chez les immigrants: Ampleur, impact, coûts et interventions		10,096			
Greenaway, Christina	Fonds de la Recherche en Santé du Québec	Les maladies infectieuses chez les immigrants: Ampleur, impact, coûts et interventions		30,764			
Greenaway, Christina	Fonds de la Recherche en Santé du Québec	Une étude de population sur l'hépatite virale chez les immigrants: fardeau, coûts et détermination de l'intervention optimale	813				
Greenaway, Christina	Instituts de Recherche en Santé du Canada	Innovative approaches for diagnosing tuberculosis in the era of HIV	7,427				
Greenaway, Christina	Instituts de Recherche en Santé du Canada	What's the damage? Impact of tuberculosis disease, infection, and treatment on health status.	11,010				
Hilzenrat, Nir	Regroupement de Compagnies, Corporations	Improved care and education for patients with Hepatitis B.	190,300				
Hiscott, John	Université McGill	Oncolytic virus therapy for ATL.		2,505			
Hiscott, John	Instituts de Recherche en Santé du Canada	Modulation of the innate antiviral immune response during primary HTLV-1 infection.		4,890			
Hiscott, John	Institut National du Cancer du Canada	Canadian oncolytic virus consortium.	52,788				
Hiscott, John	Instituts de Recherche en Santé du Canada	Regulation of Toll-like receptor-independent and independent antiviral pathways during de novo HIV-1 infection.	159,526				
Hiscott, John	Institut National du Cancer du Canada	Canadian oncolytic virus consortium.	160,856				
Hiscott, John	Instituts de Recherche en Santé du Canada	Molecular interactions regulating RIG-I signaling to the innate antiviral response.	176,816				
Hoffer, Leonard J.	Université McGill	Vitamin therapy in JGH patients		2,834			
Hoffer, Leonard J.	Lotte & John Hecht Memorial Foundation	Study - Intravenous vitamin C in combination with chemotherapy in lung cancer patients.	100,000				
Hudson, Marie	Instituts de Recherche en Santé du Canada	Longitudinal comparison of measurements for carbon monoxide lung diffusion capacity (DLCO): single breath and corrected for alveolar volume in systemic sclerosis patients		4,950			
Hudson, Marie	Instituts de Recherche en Santé du Canada	Development and validation of a patient-assessed disease activity index in systemic sclerosis.		12,039			

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Hudson, Marie	Fonds de la Recherche en Santé du Québec	Développement et validation d'un système intégré pour évaluer la fatigue liée à la sclérodermie	1,069				
Hudson, Marie	Instituts de Recherche en Santé du Canada	A new emerging team: The Canadian scleroderma research group.	9,424				
Hudson, Marie	Instituts de Recherche en Santé du Canada	Strategic training initiative - Canadian Scleroderma Research Group.	14,400				
Jagoe, Robert	Université McGill	Summer Research Work Study.		1,080			
Jagoe, Robert	Regroupement de Particuliers	Oncology Research	11,341				
Jagoe, Robert	Regroupement de Particuliers	Oncology Research	15,352				
Johnson, Nathalie	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Start-up Funds.		17,308			
Johnson, Nathalie	Fonds de la Recherche en Santé du Québec	Identification de biomarqueurs de prévision des lymphomes se présentant chez les adolescents et les jeunes adultes		25,396			
Johnson, Nathalie	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Start-up Funds.		52,740			
Johnson, Nathalie	Fondation Cole	Help develop the cell library of the Quebec Leukemia Cell Bank with young adult lymphoma cells.	4,121				
Johnson, Nathalie	Fonds de la Recherche en Santé du Québec	Identification de biomarqueurs de prévision des lymphomes se présentant chez les adolescents et les jeunes adultes	7,534				
Johnson, Nathalie	Fondation Cole	Help develop the cell library of the Quebec Leukemia Cell Bank with young adult lymphoma cells.	20,890				
Johnson, Nathalie	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Start-up Funds.	24,725				
Johnson, Nathalie	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Start-up Funds.	75,342				
Kader, Tina	Instituts de Recherche en Santé du Canada	The Metformin in women with type 2 diabetes in pregnancy trial ("MITY" "The Study")	1,900				
Kahn, Susan Rebecca	Fonds de la Recherche en Santé du Québec	Recherche épidémiologique sur les maladies thromboemboliques: conséquences et mécanismes		10,659			
Kahn, Susan Rebecca	Fonds de la Recherche en Santé du Québec	Recherche épidémiologique sur les maladies thromboemboliques: conséquences et mécanismes		37,671			
Kahn, Susan Rebecca	Sanofi-Aventis (Canada)	Thrombosis Fellowship.		60,000			
Kahn, Susan Rebecca	Instituts de Recherche en Santé du Canada	TIPPS (Thrombophilia in pregnancy prophylaxis study): A multicentre, multinational randomised control trial of prophylactic low molecular weight heparin (LMWH) in high risk pregnant thrombophilic women. CIHR 524E-CVD-9101-004	1,800				
Kahn, Susan Rebecca	Heart and Stroke Foundation of Ontario (HSFO)	NA6771-Recurrent venous thromboembolism risk stratification evaluation (REVERSE): long term follow-up to define if lifelong anticoagulation is required in high risk patients with a first unprovoked venous thromboembolism.	3,466				
Kahn, Susan Rebecca	Instituts de Recherche en Santé du Canada	GENErVTE: Gene Gene Interactions and Recurrent Venous Thromboembolism.	3,750				
Kahn, Susan Rebecca	Fondation des Maladies du Coeur de l'ontario (Toronto, Ont)	P. Wells - HSFO - Development and validation of clinical prediction rules for bleeding for patients on anticoagulant therapy for venous thromboembolism.	6,750				
Kahn, Susan Rebecca	Instituts de Recherche en Santé du Canada	Step Monitoring to improve ARTERial health (SMARTER)	9,317				
Kahn, Susan Rebecca	Regroupement de Particuliers	Thrombosis Clinic.	13,200				
Kahn, Susan Rebecca	National Institutes of Health	Pharmacomechanical catheter-directed thrombolysis for acute DVT-attract trial.	20,248				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Kahn, Susan Rebecca	Instituts de Recherche en Santé du Canada	A Pilot Study Assessing Feasibility of a Randomized, Placebo-controlled Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism (pilot PROSPER Trial: PostpaRtum PrOphylaxiS for PE Randomized C	25,291				
Kahn, Susan Rebecca	Instituts de Recherche en Santé du Canada	Furthering innovation in thrombosis research. - TRUST Registry Study.	25,741				
Kahn, Susan Rebecca	Instituts de Recherche en Santé du Canada	Randomized controlled trial of anticoagulation vs. placebo for a first symptomatic isolated distal deep-vein thrombosis (IDDVT): The CACTUS-PTS Trial.	31,543				
Kahn, Susan Rebecca	Instituts de Recherche en Santé du Canada	A randomized, placebo-controlled trial of compression stockings to prevent the post-thrombotic syndrome: The SOX Trial.	120,091				
Kahn, Susan Rebecca	Instituts de Recherche en Santé du Canada	Prospective evaluation of long-term outcomes after pulmonary embolism: The ELOPE study.	139,358				
Karaplis, Andrew C.	Fondation Canadienne du Rein	Hormonal and molecular regulation of phosphorus homeostasis.	12,301				
Karaplis, Andrew C.	Instituts de Recherche en Santé du Canada	Co-targeting parathyroid-hormone related protein (PTHrP) signaling and osteoclast activation to counter breast cancer metastasis to bone	31,642				
Karaplis, Andrew C.	Fondation Canadienne du Rein	Hormonal and molecular regulation of phosphorus homeostasis.	37,483				
Karaplis, Andrew C.	Instituts de Recherche en Santé du Canada	PTHrP and osteoblast biology: relevance to osteoporosis	82,101				
Karaplis, Andrew C.	Susan G. Komen Breast Cancer Foundation	Co-targeting Parathyroid Hormone-related Protein Signaling and Osteoclast Metabolism to Counter Breast Cancer Metastasis to Bone	99,984				
Kavan, Petr	Regroupement de Particuliers	Glaucoma unit.	5,000				
Kavan, Petr	Regroupement de Particuliers	Young adult program.	7,279				
Kleiman, Lawrence C.	Instituts de Recherche en Santé du Canada	Annealing of primer tRNA <sup>Lys3</sup> to genomic RNA in HIV-1.	86,336				
Kleiman, Lawrence C.	Instituts de Recherche en Santé du Canada		148,274				
Kleiman, Lawrence C.	National Institutes of Health	Development of the Gag/LysRS interaction as a target for anti-HIV therapy.	154,168				
Kleiman, Lawrence C.	National Institutes of Health	Development of the Gag/LysRS interaction as a target for anti-HIV therapy.	477,706				
Langleben, David	Regroupement de Particuliers	Cardiology Research.	44,527				
Lapointe, Bernard Joseph	Regroupement de Particuliers	Palliative Care Research.	3,496				
Lapointe, Bernard Joseph	Regroupement de Particuliers	Supportive Care Research.	53,538				
Leblanc, Andréa	Université McGill	The role of inflammation in regulating neuronal Caspase-6 activation in Alzheimer Disease.		2,000			
Leblanc, Andréa	Université McGill	Studies on an inhibitor of caspase-6.		2,088			
Leblanc, Andréa	Université McGill	The normal function of prion protein.		2,253			
Leblanc, Andréa	Instituts de Recherche en Santé du Canada			2,500			
Leblanc, Andréa	Université McGill	Graduate Studies in Cell Biology and Anatomy Fellowship.		4,500			
Leblanc, Andréa	Université McGill	Mode of retrotranslocation of normal prion protein into the cytosol and investigation of how similar prion mutations may alter prion retrotranslocation.		5,011			
Leblanc, Andréa	Université McGill	Mode of retrotranslocation of normal prion protein into the cytosol and investigation of how similar prion mutations may alter prion retrotranslocation.		5,836			
Leblanc, Andréa	Université McGill	The role of inflammation in regulating neuronal Caspase-6 activation in Alzheimer Disease.		8,352			
Leblanc, Andréa	Université McGill	The role of inflammation in regulating neuronal Caspase-6 activation in Alzheimer Disease.		11,671			



NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Leblanc, Andréa	Fonds de la Recherche en Santé du Québec	Études sur un inhibiteur de caspases présent dans les neurones humaines		13,808			
Leblanc, Andréa	Instituts de Recherche en Santé du Canada	Role of the cytosolic prion protein in the regulation of Bax ubiquitination and its impact on cell survival.		35,000			
Leblanc, Andréa	National Institutes of Health	Phosphorylation of prion protein as a novel mechanism for conversion	44,021				
Leblanc, Andréa	Instituts de Recherche en Santé du Canada	Role of caspases in human neuronal cell death and in Alzheimer's Disease.	61,709				
Leblanc, Andréa	Regroupement de Particuliers	Alzheimer's research funds.	63,002				
Leblanc, Andréa	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	The role of Casp6 in colon carcinogenesis.	69,041				
Leblanc, Andréa	Instituts de Recherche en Santé du Canada	Role of caspases in human neuronal cell death and in Alzheimer's Disease.	78,129				
Leblanc, Andréa	Instituts de Recherche en Santé du Canada	Regulation of prion protein expression, trafficking and function	136,212				
Lehoux, Stephanie	Université McGill	M.Sc. Program in Experimental Medicine		989			
Lehoux, Stephanie	Fonds de la Recherche en Santé du Québec	Mécanismes impliqués dans la réduction de la plaque d'athérosclérose par la contrainte de cisaillement.		18,411			
Lehoux, Stephanie	Secrétariat des Chaires de Recherche du Canada	Régulation de l'expression du récepteur AT1 de l'angiotensine par la contrainte de cisaillement: rôle dans l'athérosclérose.		50,000			
Lehoux, Stephanie	Secrétariat des Chaires de Recherche du Canada	Régulation de l'expression du récepteur AT1 de l'angiotensine par la contrainte de cisaillement: rôle dans l'athérosclérose.		50,137			
Lehoux, Stephanie	Instituts de Recherche en Santé du Canada	Athero-protective shear stress signalling in the vasculature	127,729				
Liang, Chen	Université McGill	An anti HIV activity of SAMHD1 in myeloid cell.		1,507			
Liang, Chen	China Scholarship Council (Csc)	Identification of Tat-interacting cellular factors and mechanistic study of their roles in HIV-1 replication.		4,747			
Liang, Chen	Université McGill	Étude de l'assemblage du virus d'immunodéficience humain type-1.		9,685			
Liang, Chen	Fonds de la Recherche en Santé du Québec	Étude de l'Assemblage du Virus d'Immunodéficience Humain Type-1		9,686			
Liang, Chen	Instituts de Recherche en Santé du Canada	Fusion and cell entry by oncogenic sheep retroviruses.	19,160				
Liang, Chen	Instituts de Recherche en Santé du Canada	Fusion and cell entry by oncogenic sheep retroviruses.	57,584				
Liang, Chen	Instituts de Recherche en Santé du Canada	The Botswana-Canada AIDS vaccine discovery partnership.	89,793				
Liang, Chen	Instituts de Recherche en Santé du Canada	Towards a new approach for the detection of pain in adults in critical care: near-infrared spectroscopy (NIRS).	96,770				
Liang, Chen	Instituts de Recherche en Santé du Canada	Studying the antiviral of bone marrow stromal cell antigen 2 and the countering mechanism from HIV-1 Vpu.	144,269				
Lin, Rongtuan	Université McGill	The activation of RIG-I pathway counteracts H1N1 Influenza virus replication.		835			
Lin, Rongtuan	Instituts de Recherche en Santé du Canada	Cross-talk between host antiviral and apoptotic signaling pathways in de novo Dengue virus infection.	18,750				
Lin, Rongtuan	Instituts de Recherche en Santé du Canada	Oncolytic virus therapy for HTLV-1 induced adult T cell leukemia.	149,738				
Lin, Rongtuan	Instituts de Recherche en Santé du Canada	Innate immunity and Hepatitis C virus infection.	174,307				
Lin, Rongtuan	Instituts de Recherche en Santé du Canada	Molecular interactions regulating RIG-I signaling to the innate antiviral response.	176,816				
Lipman, Mark L.	Regroupement de Particuliers	Renal Research.	125,473				
Lipman, Mark L.	Regroupement de Particuliers	Hemodialysis Research.	167,219				
Mann, Koren	Université McGill	The role of tungsten in preB acute lymphocytic leukemogenesis.		1,209			

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Mann, Koren	Université McGill	The role of macrophages polarization in arsenic carcinogenicity		2,000			
Mann, Koren	Université McGill	The potential of tungsten to induce DNA damage in B-cells in vivo		2,000			
Mann, Koren	Université McGill	Mechanisms of arsenic induced apoptosis		2,250			
Mann, Koren	Université McGill	The role of tungsten in preB acute lymphocytic leukemogenesis.		9,033			
Mann, Koren	Fonds de la Recherche en Santé du Québec	Effets toxicologiques des métaux.		55,025			
Mann, Koren	Leukemia Research Foundation	The role of tungsten exposure in the development of preB acute lymphoblastic leukemia.	24,765				
Mann, Koren	Instituts de Recherche en Santé du Canada	Mechanisms of arsenic-enhanced atherosclerosis.	27,290				
Mann, Koren	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	The role of tungsten exposure in the development of preB acute lymphoblastic leukemia.	45,672				
Mann, Koren	National Institutes of Health	The role of LXR/RXR heterodimers in arsenic-induced atherosclerosis.	57,894				
Mann, Koren	Instituts de Recherche en Santé du Canada	Mechanisms of arsenic-enhanced atherosclerosis.	91,507				
Michel, Caroline	National Institutes of Health	Xanthine oxidase inhibition for hyperuricemic heart failure patients.	19,705				
Michel, Caroline	Aventis Pharma	Heart failure clinic equipment donation.	229,789				
Miller, Mark A.	Santé Canada	Vancomycin-resistant enterococci (VRE) occurrence report protocol Canadian nosocomial infection surveillance program (CNISP).	23,660				
Miller, Wilson	Instituts de Recherche en Santé du Canada	Investigating the molecular mechanisms of retinoids as anti-virals in paramyxovirus infections		875			
Miller, Wilson	Université McGill	Examine the role of EIF4E during the TGF-beta induced epithelial to mesenchyme-like transition (EMT).		2,000			
Miller, Wilson	Université McGill	Correlating mutations in histone modifying enzymes to sensitivity to histone deacetylase inhibitor in B-cell non-hodgkin's lymphoma.		2,000			
Miller, Wilson	Instituts de Recherche en Santé du Canada	Improving combination therapies involving histone deacetylase inhibitors and DNA methyltransferase inhibitors in hematological malignancies		3,531			
Miller, Wilson	Université McGill	Mechanisms of the anti-cancer actions of arsenic.		4,945			
Miller, Wilson	Fondation Cole	Cole Foundation Fellowship Programme		5,440			
Miller, Wilson	Fondation Cole	By coupling molecules with retinoid and histone deacetylase inhibitor (HDACi) activity we're hoping to improve anti-neoplastic efficacy. The aim of the project is to explore the effects of this novel type of drug.		5,440			
Miller, Wilson	Instituts de Recherche en Santé du Canada	Improving combination therapies involving histone deacetylase inhibitors and DNA methyltransferase inhibitors in hematological malignancies		10,759			
Miller, Wilson	Fondation Cole	Cole Foundation Fellowship Programme		16,575			
Miller, Wilson	Fondation Cole	By coupling molecules with retinoid and histone deacetylase inhibitor (HDACi) activity we're hoping to improve anti-neoplastic efficacy. The aim of the project is to explore the effects of this novel type of drug.		16,575			
Miller, Wilson	Regroupement de Particuliers	8th International Conference of differentiation therapy - Montreal October 3-6,1999.	6,425				
Miller, Wilson	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Ribavirin as a breast cancer therapeutic.	36,822				
Miller, Wilson	American Association For Cancer Research (Philadelphia, Pa)	Targeting eIF4E with ribavirin in poor prognosis breast cancer.	66,748				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Miller, Wilson	Instituts de Recherche en Santé du Canada	Molecular mechanisms of retinoids as anti-virals in respiratory virus infections	68,988				
Miller, Wilson	Leukemia and Lymphoma Society	CRU - A phase II study of Ribavirin in refractory or relapsed acute myelocytic leukemia M4 and M5 subtypes (Protocol # Borden-001-002). LLS - The eukaryotic translation initiation factor eIF4E: a novel therapeutic target in myeloid leukemia.	69,679				
Miller, Wilson	Instituts de Recherche en Santé du Canada	Targeting the eukaryotic translation factor eIF4E with ribavirin in breast cancer.	70,880				
Miller, Wilson	Samuel Waxman Cancer Research Foundation	Development of novel anti-cancer therapies using arsenic trioxide.	78,428				
Miller, Wilson	Instituts de Recherche en Santé du Canada	Novel mediators of response and resistance to epigenetic therapy of leukemia.	138,305				
Miller, Wilson	Instituts de Recherche en Santé du Canada		162,500				
Miller, Wilson	Instituts de Recherche en Santé du Canada		170,356				
Monette, Johanne	Instituts de Recherche en Santé du Canada		4,514				
Monette, Johanne	Instituts de Recherche en Santé du Canada		6,560				
Monette, Johanne	Fonds de la Recherche en Santé du Québec	Utilisation des services médicaux d'urgence et hospitaliers chez la clientèle âgée de 75 ans et plus : Quel est l'impact de l'accès aux ressources médicales et communautaires de première ligne ?	20,712				
Mouland, Andrew	Université McGill	Molecular & virological studies of HIV-1.		3,881			
Mouland, Andrew	Université McGill	The RNA and cell biology of HIV-1 infection.		8,901			
Mouland, Andrew	National Commission of Scientific Research and Technology (Conicyt) (Chile)	HIV integrase.		13,199			
Mouland, Andrew	Instituts de Recherche en Santé du Canada	Sheldon Biotechnology Centre: Surface Plasmon Resonance Facility.	7,966				
Mouland, Andrew	Canadian Foundation For Aids Research (Canfar)	Implications of upframeshift suppressor protein 1 (UPF1) in HIV-1 genomic RNAQ fate.	40,000				
Mouland, Andrew	Canadian Foundation For Aids Research (Canfar)	Implications of upframeshift suppressor protein 1 (UPF1) in HIV-1 genomic RNAQ fate.	40,110				
Mouland, Andrew	Instituts de Recherche en Santé du Canada		109,807				
Mouland, Andrew	Instituts de Recherche en Santé du Canada	Understanding how the HIV-1-dependent ribonucleoprotein counters host stress responses	134,164				
Panasci, Lawrence	Université McGill	Synergism of Irinotecan and Oxaliplatin in the treatment of colon cancer cells by the PARP inhibitor ABT-888.		2,000			
Panasci, Lawrence	Université McGill	PI3K inhibitors in CLL therapy.		4,050			
Panasci, Lawrence	Institut National du Cancer du Canada	Sorafenib in breast cancer: A laboratory-based approach for a rational clinical development. (Post-MD Research Fellowship).		12,115			
Panasci, Lawrence	Régroupement de Particuliers	Donations.	5,070				
Panasci, Lawrence	Fonds de la Recherche en Santé du Québec	Étude prospective pour identifier et valider des biomarqueurs de résistance thérapeutique dans le cancer colorectal métastatique	17,666				
Panasci, Lawrence	Instituts de Recherche en Santé du Canada	c-Abl-directed molecular re-engineering of chlorambucil to offer new therapeutic options to patients with chronic lymphocytic leukemia (CLL).	37,410				
Panasci, Lawrence	Fonds de la Recherche en Santé du Québec	Étude prospective pour identifier et valider des biomarqueurs de résistance thérapeutique dans le cancer colorectal métastatique	71,450				
Pantopoulos, Kostas	John S.Latsis Ileians' Scholarships Foundation	The role of protein H <sub>2</sub> V on the pathogenesis of hemochromatosis. The role of hemojuvelin in iron homeostasis.		10,652			

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Pantopoulos, Kostas	Fonds de la Recherche en Santé du Québec	Validation et caractérisation d'un mécanisme alternatif de traduction de l'ARN messager de la ferritine		11,703			
Pantopoulos, Kostas	Fonds de la Recherche en Santé du Québec	Regulation du métabolisme du fer		17,765			
Pantopoulos, Kostas	Fonds de la Recherche en Santé du Québec	Regulation du métabolisme du fer		32,277			
Pantopoulos, Kostas	Instituts de Recherche en Santé du Canada	Iron metabolism in health and disease: The IRE/IRP system and beyond.	128,656				
Papageorgiou, Apostolos	Centre de Recherche du Chu Sainte-Justine	Placental insufficiency and aortic isthmus flow (PIAF).	9,000				
Papageorgiou, Apostolos	Regroupement de Particuliers	Neonatology Research.	26,346				
Paudel, Hemant	Société Alzheimer du Canada	Transcriptional dysregulation in Alzheimer's Disease.		8,573			
Paudel, Hemant	China Scholarship Council (Csc)			9,468			
Paudel, Hemant	Société Alzheimer du Canada	Transcriptional dysregulation in Alzheimer's Disease.		11,981			
Paudel, Hemant	Sir Mortimer B. Davis - Hôpital Général Juif	Development of a PET radioligand for phosphorylated TAU.	16,044				
Paudel, Hemant	Société Alzheimer du Canada	EGR-1 and Alzheimer's disease	18,544				
Paudel, Hemant	Conseil de Recherches en Sciences Naturelles et Génie du Canada	Phosphorylation of protein phosphatase 1 during neuronal differentiation.	34,000				
Paudel, Hemant	Instituts de Recherche en Santé du Canada	Neurofibrillary pathology and amyloidogenesis in Alzheimer's disease: mechanistic insights.	65,138				
Paudel, Hemant	Instituts de Recherche en Santé du Canada	Tau protein and Alzheimer's disease.	67,405				
Pollak, Michael	Université McGill	Suppression of pyruvate metabolism in cancer cells		1,670			
Pollak, Michael	Université McGill	Examination of intracellular signaling downstream of the insulin and IGF-1 receptor in tumor tissue in an in vivo model of the metabolic syndrome and type 2 diabetes.		2,000			
Pollak, Michael	Université McGill	Oncometabolics.		2,521			
Pollak, Michael	Instituts de Recherche en Santé du Canada			2,685			
Pollak, Michael	Novo Nordisk A/S (Danemark)	New in vivo models for assessment of mitogenic and tumor growth promoting effects of insulin and insulin analogues.		3,582			
Pollak, Michael	Société de Recherche sur Le Cancer Inc		4,339				
Pollak, Michael	Jewish Hospital Foundation	Segal-Goodman distinguished lectures in cancer.	5,000				
Pollak, Michael	National Institutes of Health	BFIT Study: Analysis of C-peptide levels and endometrial cancer. BFIT Study: Analysis of high molecular weight (HMW) adiponectin in relation to endometrial cancer.	8,433				
Pollak, Michael	Société Canadienne du Cancer	Effects of metformin on colorectal epithelial cell proliferation.	16,027				
Pollak, Michael	Prostate Cancer Foundation (PCF)	Prevention of treatment and disease-related morbidity during androgen deprivation therapy: A multicenter proposal.	24,765				
Pollak, Michael	National Institutes of Health	Prospective evaluation of insulin-like growth factor 1 plasma/serum biomarkers and multiple myeloma.	44,166				
Pollak, Michael	Cancer de la Prostate Canada	Influence of insulin on androgen production.	45,205				
Pollak, Michael	Institut National du Cancer du Canada	Modifiable dietary determinants of levels of IGF-1, insulin, and risk of colorectal cancer and lethal prostate cancer.	45,803				
Pollak, Michael	Sir Mortimer B. Davis - Hôpital Général Juif	A Pilot Clinical Trial of Metformin in Prostate Cancer.	50,000				
Pollak, Michael	National Institutes of Health	Risk of multiple myeloma in relation to plasma adipokine levels: a nested case-control study in the prostate, lung, colorectal and ovarian cancer screening trial.	55,288				
Pollak, Michael	National Institutes of Health	Epidemiologic studies of diet and cancer in Hawaii.	80,128				
Pollak, Michael	Instituts de Recherche en Santé du Canada	Defining and Applying "Oncometabolism": A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities.	80,724				
Pollak, Michael	Société Canadienne du Cancer	Effects of metformin on colorectal epithelial cell proliferation.	81,696				
Pollak, Michael	Regroupement de Particuliers	Breast cancer research.	112,677				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Pollak, Michael	Institut National du Cancer du Canada	Modifiable dietary determinants of levels of IGF-1, insulin, and risk of colorectal cancer and lethal prostate cancer.	127,091				
Ponka, Prem	Société Canadienne du Sang	Chelation, mobilization and metabolism of storage iron.	33,170				
Ponka, Prem	Instituts de Recherche en Santé du Canada	Chelation, mobilization and metabolism of storage iron.	104,213				
Ponka, Prem	Instituts de Recherche en Santé du Canada	Regulation of iron metabolism and heme synthesis in erythroid cells.	133,831				
Portnoy, Joseph	Regroupement de Particuliers	Quality of care research.	6,076				
Portnoy, Joseph	Regroupement de Particuliers	Infectious disease research.	9,336				
Richard, Stéphane	Université McGill	Identification of DNA damage-induced arginine methylated proteins.		2,967			
Richard, Stéphane	Université McGill	Role of post-translation modifications in splicing and DNA damage.		4,945			
Richard, Stéphane	Société Canadienne de la Sclérose en Plaques	Identification of the RNA targets bound by the quaking RNA binding proteins.		5,000			
Richard, Stéphane	Fonds Québécois de la Recherche sur La Nature et les Technologies			6,329			
Richard, Stéphane	Fonds de la Recherche en Santé du Québec	Rôles des protéines KH liant l'ARN et la méthylation des arginines: Implications pour la sclérose en plaques et le cancer.		7,418			
Richard, Stéphane	Société Canadienne de la Sclérose en Plaques	Study microRNA and quaking RNA binding protein function on oligodendrocyte differentiation.		9,643			
Richard, Stéphane	Fonds de la Recherche en Santé du Québec	Identification et étude de protéines arginine-méthylées lors de la signalisation du dommage à l'ADN dans les cellules cancéreuses		11,301			
Richard, Stéphane	Université McGill	Assessing the role of sumoylation of protein arginine methyltransferase.		15,055			
Richard, Stéphane	Fonds de la Recherche en Santé du Québec	Définir le rôle de l'arginine méthyltransférase PRMT7 dans la réponse cellulaire aux dommages de l'ADN.		30,000			
Richard, Stéphane	Instituts de Recherche en Santé du Canada	Regulators mediating the proinflammatory cytokine response in uterine smooth muscle cells.		36,667			
Richard, Stéphane	Instituts de Recherche en Santé du Canada	Lysine methylation of non-histone proteins.		45,000			
Richard, Stéphane	Institut National du Cancer du Canada	The role of arginine methylation of MRE11 in mediating the DNA damage response.	30,311				
Richard, Stéphane	Institut National du Cancer du Canada	The role of the QUAKING RNA binding proteins in tumorigenesis.	30,412				
Richard, Stéphane	Institut National du Cancer du Canada	Role of the STAR protein Sam68 in cancer: Regulation by tyrosine kinases.	34,169				
Richard, Stéphane	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	The role of H2Az lysine methylation by SETD6 in estrogen-dependent transcription and breast cancer.	36,822				
Richard, Stéphane	Institut National du Cancer du Canada	The role of arginine methylation of MRE11 in mediating the DNA damage response.	92,362				
Richard, Stéphane	Institut National du Cancer du Canada	The role of the QUAKING RNA binding proteins in tumorigenesis.	92,671				
Richard, Stéphane	Institut National du Cancer du Canada	Role of the STAR protein Sam68 in cancer: Regulation by tyrosine kinases.	104,120				
Richard, Stéphane	Société Canadienne de la Sclérose en Plaques	The role of the quaking protein in oligodendrocyte physiology and myelination.	106,360				
Richard, Stéphane	Instituts de Recherche en Santé du Canada		137,473				
Richard, Stéphane	Instituts de Recherche en Santé du Canada	The role of the STAR RNA binding protein Sam68 in regulating cell migration and proliferation in cancer.	156,661				
Richard, Stéphane	Instituts de Recherche en Santé du Canada		175,420				
Richards, Brent	Instituts de Recherche en Santé du Canada	Genetic and environmental determinants of vitamin D levels in Canadians.		29,712			

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Richards, Brent	Instituts de Recherche en Santé du Canada			45,000			
Richards, Brent	Instituts de Recherche en Santé du Canada	The role of rare genetic variants in common disease.		45,000			
Richards, Brent	Fonds de la Recherche en Santé du Québec	Épidémiologie génétique des fractures ostéoporotiques; des gènes de susceptibilité aux populations susceptibles	2,473				
Richards, Brent	Instituts de Recherche en Santé du Canada		5,000				
Richards, Brent	Fonds de la Recherche en Santé du Québec	Épidémiologie génétique des fractures ostéoporotiques; des gènes de susceptibilité aux populations susceptibles	7,534				
Richards, Brent	Génome Québec	GRADE: Genomics in drug repositioning and adverse effects.	10,000				
Richards, Brent	Fondation Canadienne Pour l'innovation (Fci)	A Laboratory to Study the Genetic Epidemiology of Aging-Related Disease	22,487				
Richards, Brent	Instituts de Recherche en Santé du Canada	Pinpointing causal variants for osteoporosis.	27,224				
Richards, Brent	King's College London	Standard operating procedures.	75,957				
Richards, Brent	Consortium Québécois sur La Découverte du Médicament (Cqdm)	Identification de cibles thérapeutiques cruciales pour les maladies auto-immunes. - Pinpointing critical drug targets for autoimmune disease.	300,000				
Schiffirin, Ernesto	Fondation des Maladies du Coeur du Canada (FMCC)	Remodelage des artères de petit et gros calibre dans l'insuffisance rénale chronique.		8,078			
Schiffirin, Ernesto	Fondation des Maladies du Coeur du Canada (FMCC)	Remodelage des artères de petit et gros calibre dans l'insuffisance rénale chronique.		9,890			
Schiffirin, Ernesto	University of Barcelona	Dr. Cristina Sierra - Paid Permit from the Hospital Clinic of Barcelona in Spain.		12,139			
Schiffirin, Ernesto	Kao Corporation (Japan)	Research on vascular diseases in hypertension: Role of endothelin, PPARs and T-lymphocytes.		40,000			
Schiffirin, Ernesto	Secrétariat des Chaires de Recherche du Canada	Remodeling of blood vessels in hypertension.		49,863			
Schiffirin, Ernesto	Secrétariat des Chaires de Recherche du Canada	Remodeling of blood vessels in hypertension.		150,549			
Schiffirin, Ernesto	Regroupement de Particuliers	Cardiohypertension research "Fonds d'urgence".	684				
Schiffirin, Ernesto	Instituts de Recherche en Santé du Canada	Congenital nephron deficit and essential hypertension.	56,444				
Schiffirin, Ernesto	Juvenile Diabetes Research Foundation International	Nox-derived Rox: renal and vascular complications of type 1 diabetes.	73,769				
Schiffirin, Ernesto	Instituts de Recherche en Santé du Canada	Vascular remodeling in hypertension: From genes to mice to humans.	112,147				
Schiffirin, Ernesto	Instituts de Recherche en Santé du Canada	T-regulatory cells and vascular injury in hypertension	156,659				
Schiffirin, Ernesto	Instituts de Recherche en Santé du Canada	Endothelin, vascular inflammation and injury, and hypertension.	159,344				
Schipper, Hyman Morris	National Institutes of Health	Clinical assessment of patients with AD and NEC individuals.	59,313				
Schipper, Hyman Morris	Instituts de Recherche en Santé du Canada		136,571				
Schirmacher, Ralf	Secrétariat des Chaires de Recherche du Canada	Synthesis of novel radiopharmaceuticals for PET in neurology and oncology.		100,000			
Sheppard, Richard	National Institutes of Health	Immune activation and myocardial recovery in peripartum cardiomyopathy.	1,865				
Small, David	Regroupement de Particuliers	Airway center.	42,690				
Suissa, Samy	Instituts de Recherche en Santé du Canada	Propensity scores and marginal structural models in drug safety research	7,033				
Suissa, Samy	Instituts de Recherche en Santé du Canada	CIHR - Quebec Respiratory Health Training Program	8,125				
Suissa, Samy	Instituts de Recherche en Santé du Canada	Multiple medication use in the Quebec elderly and the risk of motor vehicle crash.	93,926				
Suissa, Samy	Instituts de Recherche en Santé du Canada	Canadian Network for Observational Drug Effect Studies.	3,180,100				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Szilagyi, Andrew	Institut Danone/Dannon	Differential biologic impact of lactose consumption in lactase persistent and non-persistent populations: Evaluation of microflora and insulin/glycemic response.	1,114				
Szilagyi, Andrew	Regroupement de Particuliers	Fructose study.	1,318				
Tagalakis, Vicky	Fonds de la Recherche en Santé du Québec	Recherche épidémiologique et pharmacoépidémiologique en thrombose veineuse		8,562			
Tagalakis, Vicky	Fonds de la Recherche en Santé du Québec	Recherche épidémiologique et pharmacoépidémiologique en thrombose veineuse		26,666			
Tagalakis, Vicky	Instituts de Recherche en Santé du Canada	Lots about clots and cancer: what cancer patients and their families should know about deep vein thrombosis and pulmonary embolism.	3,000				
Tagalakis, Vicky	Fondation des Maladies du Coeur du Québec	Screening for previously undiagnosed malignancy in patients with unprovoked venous thromboembolism: a randomized controlled trial using comprehensive computed tomography of the abdomen/pelvis.	4,945				
Tagalakis, Vicky	Fondation des Maladies du Coeur du Québec	Screening for previously undiagnosed malignancy in patients with unprovoked venous thromboembolism: a randomized controlled trial using comprehensive computed tomography of the abdomen/pelvis.	12,055				
Tagalakis, Vicky	Fondation des Maladies du Coeur du Québec		25,000				
Therrien, Judith	Instituts de Recherche en Santé du Canada	Analyzing and Reducing Health disparities in Adult Congenital Heart Disease.	13,815				
Thombs, Brett	Instituts de Recherche en Santé du Canada	Reporting of conflicts of interest in Coshrane reviews of trials of pharmacological treatments.		1,500			
Thombs, Brett	Fonds de la Recherche en Santé du Québec	Améliorer le dépistage de la dépression dans les cliniques de Rhumatologie: Détection de la dépression persévérante versus aiguë dans les patients souffrant de la sclérodémie		4,377			
Thombs, Brett	Fonds de la Recherche en Santé du Québec	La Dissatisfaction avec l'Image Corporelle: Développement d'une Echelle auprès de Patients Atteints de Sclérodémie		4,698			
Thombs, Brett	Instituts de Recherche en Santé du Canada			4,950			
Thombs, Brett	Université McGill	Development and validation of a pruritus measure for patients with systemic sclerosis.		5,836			
Thombs, Brett	Instituts de Recherche en Santé du Canada	Improving depression screening in rheumatology clinics: Detection of persistent versus acute depression in Scleroderma patients.		6,000			
Thombs, Brett	Instituts de Recherche en Santé du Canada	Development and validation of a fatigue assessment protocol for Scleroderma.		7,308			
Thombs, Brett	Instituts de Recherche en Santé du Canada	Improving depression screening in rheumatology clinics: Detection of persistent versus acute depression in Scleroderma patients.		7,308			
Thombs, Brett	Instituts de Recherche en Santé du Canada	Prevalence of major depression in patients with cardiovascular disease: a meta-analysis of the role of the method of depression assessment		7,308			
Thombs, Brett	Fonds de la Recherche en Santé du Québec	Améliorer l'évaluation de la fatigue en sclérodémie pour en arriver à une mesure uniforme		8,753			
Thombs, Brett	Fonds de la Recherche en Santé du Québec	La fréquence de la dépression majeure dans la maladie cardiovasculaire: Une méta-analyse du rôle de la méthode d'évaluation de la dépression		15,000			
Thombs, Brett	Instituts de Recherche en Santé du Canada	Development of assessment tools for fatigue related to systemic sclerosis: Research, diagnostic, and screening applications.		60,000			

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Thombs, Brett	Fonds de la Recherche en Santé du Québec	Développement et validation d'un système intégré pour évaluer la fatigue liée à la sclérodémie	1,069				
Thombs, Brett	American College of Rheumatology (Atlanta, Ga)	ACR REF/Abbott Health Professional Graduate Student Research Preceptorship.	1,509				
Thombs, Brett	Fonds de la Recherche en Santé du Québec	Écoles, culture et santé mentale: une articulation à repenser dans une société en transformation	1,537				
Thombs, Brett	Fonds de la Recherche en Santé du Québec	La sclérodémie: Un Programme d'Etude Portant sur l'Expérience de la Maladie selon la Perspective des Patients	3,709				
Thombs, Brett	Instituts de Recherche en Santé du Canada		5,531				
Thombs, Brett	Instituts de Recherche en Santé du Canada		8,515				
Thombs, Brett	Instituts de Recherche en Santé du Canada	Consortium for behavioural, psychological , and educational trials in Scleroderma.	9,200				
Thombs, Brett	Instituts de Recherche en Santé du Canada	A new emerging team: The Canadian scleroderma research group.	9,424				
Thombs, Brett	Scleroderma Society of Canada	International Consortium for Behavioral/Educational/Psychological Interventions for Scleroderma.	12,500				
Thombs, Brett	Instituts de Recherche en Santé du Canada	Scleroderma Patient-Centred Intervention Network (SPIN) planning meeting.	20,885				
Thombs, Brett	Instituts de Recherche en Santé du Canada	Strategic training initiative - Canadian Scleroderma Research Group.	21,600				
Thombs, Brett	Scleroderma Society of Ontario	International Consortium for Behavioral/Educational/Psychological Interventions for Scleroderma.	25,000				
Thombs, Brett	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	International Consortium for Behavioral/Educational/Psychological Interventions for Scleroderma.	37,500				
Thombs, Brett	Instituts de Recherche en Santé du Canada	Emerging Team: The Scleroderma patient-centered intervention Network.	49,996				
Thombs, Brett	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	International Consortium for Behavioral/Educational/Psychological Interventions for Scleroderma.	75,000				
Thombs, Brett	Instituts de Recherche en Santé du Canada	Will routine depression screening benefit patients in cardiovascular care settings? An updated systematic review.	85,091				
Tischkowitz, Marc	Fonds de la Recherche en Santé du Québec	A la recherche des variants de séquences et des profils de méthylation des gènes de réparation de l'ADN qui modulent la présentation clinique et la réponse au		9,111			
Tischkowitz, Marc	Ministère du Développement Economique, de l'innovation et de l'exportation (MDEIE)	Séquençage de nouvelle génération en génétique moléculaire pour le cancer du sein héréditaire - une nouvelle stratégie émergente	746				
Tischkowitz, Marc	Ministère du Développement Economique, de l'innovation et de l'exportation (MDEIE)	Séquençage de nouvelle génération en génétique moléculaire pour le cancer du sein héréditaire - une nouvelle stratégie émergente	746				
Tischkowitz, Marc	Ministère du Développement Economique, de l'innovation et de l'exportation (MDEIE)	Séquençage de nouvelle génération en génétique moléculaire pour le cancer du sein héréditaire - une nouvelle stratégie émergente	1,356				
Tischkowitz, Marc	Ministère du Développement Economique, de l'innovation et de l'exportation (MDEIE)	Séquençage de nouvelle génération en génétique moléculaire pour le cancer du sein héréditaire - une nouvelle stratégie émergente	3,082				
Tischkowitz, Marc	Mendon F. Schutt Family Fund	Screening DICER-like families for large deletions in DICER1 or for mutations or deletions of DICER1-like genes.	3,735				
Trifiro, Mark A	Sir Mortimer B. Davis - Hôpital Général Juif	Proteomic analysis of surface receptors of scleroderma fibroblasts		3,939			



NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Trifiro, Mark A	Instituts de Recherche en Santé du Canada	Expression profiling of keratinocytes in scleroderma.		4,950			
Trifiro, Mark A	Saudi Arabian Cultural Bureau in Canada	AR Androgen receptor ubiquitination.		8,744			
Trifiro, Mark A	Conseil de Recherches en Sciences Naturelles et Génie du Canada	Miniaturized nanoplasmonic biosensors for infectious diseases detection.	1,598				
Trifiro, Mark A	Université McGill	McGill / GSK Lecture on Metabolism.		4,638			
Trifiro, Mark A	Conseil de Recherches en Sciences Naturelles et Génie du Canada	Miniaturized nanoplasmonic biosensors for infectious diseases detection.	17,170				
Trifiro, Mark A	Scleroderma Society of Ontario	Bench Research Funding	25,000				
Trifiro, Mark A	Cancer de la Prostate Canada	AR-mediate alternative RNA splicing - Impact on prostate cancer progression.	45,205				
Vedel, Isabelle	Instituts de Recherche en Santé du Canada		4,514				
Vedel, Isabelle	Instituts de Recherche en Santé du Canada		8,493				
Vedel, Isabelle	Ministère de la Santé et des Services Sociaux (Québec)	Diagnostic et prise en charge de la démence au sein des GMF: bilan de l'implantation des interventions pilotes.	21,871				
Wainberg, Mark A.	Université McGill	Drug resistance in HIV integrase.		865			
Wainberg, Mark A.	Université de Montréal	Bourse Departementale		2,102			
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	Defining effective anti-viral combinations in order to decrease the sexual transmission of HIV.		2,500			
Wainberg, Mark A.	Réseau Canadien sur les Essais Cliniques du HIV	Characterising the sensitivity of CCR5 co-receptor inhibitor resistant HIV-1 to neutralising antibodies.		13,599			
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	CIHR MD/Ph.D. Studentships.		22,000			
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	The contribution of cellular PRMT6 to HIV-1 pathogenesis.		22,000			
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	Drug resistance of HIV to second generation integrase inhibitors.		32,500			
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	Addition of exogenous Tat during early infection to inhibit the establishment of latency.		35,000			
Wainberg, Mark A.	Réseau Canadien sur les Essais Cliniques du HIV	HIV-1 subtype-specificity and resistance to integrase inhibitors.		41,438			
Wainberg, Mark A.	Ministère des Relations Internationales du Québec	Characterization of drug resistant HIV circulating in Shandong province.	2,260				
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada		10,000				
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	Infection of the put by HIV-1.	12,900				
Wainberg, Mark A.	Canadian Foundation For Aids Research (Canfar)	Are there HIV-1 subtype specific differencs in resistance to integrase inhibitors?	39,000				
Wainberg, Mark A.	Canadian Foundation For Aids Research (Canfar)	Are there HIV-1 subtype specific differencs in resistance to integrase inhibitors?	40,110				
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	Methylation of HIV viral proteins as key steps in viral replication.	55,595				
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	Studies on HIV integrase as key components of effective therapy: Molecular pathogenesis studies.	88,538				
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	The impact of HIV drug resistance mutations in different viral subtypes on viral fitness and phenotype.	91,507				
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	Patterns of drug resistance and viral evolution in patients undergoing primary HIV-infection.	96,413				
Wainberg, Mark A.	Centre de Recherches Pour Le Développement International (Crdi)	TanZamBo capacity building for HIV prevention research network.	142,680				
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	Regulation of Toll-like receptor-independent and independent antiviral pathways during de novo HIV-1 infection.	159,526				
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada		166,667				
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	The Botswana-Canada AIDS vaccine discovery partnership.	224,483				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Wainberg, Mark A.	Instituts de Recherche en Santé du Canada	The Canadian HIV Trials Network	303,218				
Wainberg, Mark A.	National Institutes of Health	HIV risk dynamics, genetic patterns, and control.	611,697				
Warshawsky, Paul	Regroupement de Particuliers	ICU Surgical Research.	12,840				
Wassmann, Sven	Secrétariat des Chaires de Recherche du Canada			50,000			
Wassmann, Sven	Secrétariat des Chaires de Recherche du Canada			50,137			
Wassmann, Sven	Instituts de Recherche en Santé du Canada		79,025				
<b>JGH Foundation (including designated donations, bequests and endowments)</b>							
Lipman M.	Grouping of Canadian Individuals	Hemodialysis Research.					175,569
Lipman M.	Grouping of Canadian Individuals	Renal Research.					126,334
Lipman M.	Grouping of Canadian Individuals	Research Nephrology					204
M. Tamilia	Grouping of Canadian Individuals	Thyroid Tumor Research.					1,439
Michel, C.	Grouping of Canadian Individuals	R & D					9,415
Miller M.	Grouping of Canadian Individuals	Infectious Diseases Research.					5,009
Miller M.	Grouping of Canadian Individuals	R & D					5,000
Miller W.	Grouping of Canadian Individuals	R & D					21,122
Miller W.	Grouping of Canadian Individuals	8th Int. Conf. of Differentiation Therapy, Mtl, QC 1999					6,425
Panasci L.	Grouping of Canadian Individuals	Donations.					5,070
Pollak M.	Grouping of Canadian Individuals	Breast Cancer Research.					149,221
Pollak M.	Grouping of Canadian Individuals	Cpru - Stroll - Cancer Screening.					52,623
Portnoy J.	Grouping of Canadian Individuals	Infectious Diseases Research.					204,011
Portnoy J.	Grouping of Canadian Individuals	Infectious Disease Research.					11,270
Portnoy J.	Grouping of Canadian Individuals	Quality of Care Research.					6,076
Richard S B.	Grouping of Canadian Individuals	R & D					12,400
Rudski, L	Grouping of Canadian Individuals	R & D					14,920
Schiffrin A.	Grouping of Canadian Individuals	Diabetes Research.					31
Schiffrin, E.	Grouping of Canadian Individuals	Cardiovascular Prevention Centre.					28,835
Schiffrin, E.	Grouping of Canadian Individuals	Dr. E. Schiffrin-Dept. Medecine Endow					19,848
Schiffrin, E.	Grouping of Canadian Individuals	Dr. E. Schiffrin-Dept. Medecine Endow (Auxiliary)					3,784
Schiffrin, E.	Grouping of Canadian Individuals	Cardiohypertension Research - ""Fonds D'urgence"".					684
Schipper H.	Grouping of Canadian Individuals	Alzheimer's Research.					205
Schondorf R.	Grouping of Canadian Individuals	Autonomic Dysfunction Research.					145
Schweitzer M.	Grouping of Canadian Individuals	Lipid Research.					10,000
Schweitzer M.	Grouping of Canadian Individuals	Cardiac Endocrinology Research.					4,035
Sebag I.	Grouping of Canadian Individuals	Cardiology Research.					1,063
Small D	Grouping of Canadian Individuals	Pulmonary Research.					60,067
Suissa S.	Grouping of Canadian Individuals	Priv-Suissa S.-Pharmacoepidemiology					26,000
Szilagyi A.	Grouping of Canadian Individuals	Fructose Study.					1,318
Therrien	Grouping of Canadian Individuals	Cardiology Research.					33,837
Trifiro M.	Grouping of Canadian Individuals	Endocrinology Research and Development.					144,078
Trifiro M.	Grouping of Canadian Individuals	Genetics Research.					95,031
Trifiro M.	Grouping of Canadian Individuals	Kennedy Disease.					4,271
Trifiro M.	Grouping of Canadian Individuals	Insulin Fund.					2,936
Trifiro M.	Grouping of Canadian Individuals	Endocrinology Research.					656
Trifiro M.	Grouping of Canadian Individuals	Medical Genetics Research.					362
Trifiro M.	Grouping of Foreign Individuals	Diabetes Research.					61
Wainberg M.	Grouping of Canadian Individuals	Québec Conference.					23,000
Wainberg M.	Grouping of Canadian Individuals	R & D					16,066
Wainberg M.	Grouping of Canadian Individuals	Aids Research.					1,276
Warshawsky Paul	Grouping of Canadian Individuals	ICU Surgical Research.					16,656

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
<b>Industrial Contracts</b>							
Agulnik, Jason	Boehringer Ingelheim (Canada) Ltd	Multi-country, cross-sectional, prospective quality of life survey of patients with advanced NSCLC.			12,012		
Agulnik, Jason	Boehringer Ingelheim (Canada) Ltd	A multi-center, randomized, double-blind, phase III trial to investigate the efficacy and safety of oral BIBF1120 plus standard Pemetrexed therapy in patients with stage IIIB/IV or recurrent non-smokers.			16,829		
Agulnik, Jason	Glaxo Wellcome Inc.	109493: A double-blind, randomized, placebo-controlled phase III study to assess the efficacy of recMAGE-A3-A3+ antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with MAGE-A3-positive non-small cell lung cancer.			29,168		
Agulnik, Jason	Morphotek Inc	A randomized double-blind, placebo-controlled, study of the safety and efficacy of Farletuzumab in combination with a platinum containing doublet in chemotherapy-naïve subjects with stage IV adenocarcinoma of the lung.			68,412		
Assouline, Sarit	Hoffmann-La Roche Limitée, Canada	CRU - A two-stage phase 1b study to investigate the pharmacokinetics, safety and tolerability of rituximab subcutaneous (SC) formulation in patients with follicular lymphoma (FL) as part of maintenance treatment.			1,000		
Assouline, Sarit	Hoffmann-La Roche Limitée, Canada	CRU - A two-stage phase 1b study to investigate the pharmacokinetics, safety and tolerability of rituximab subcutaneous (SC) formulation in patients with follicular lymphoma (FL) as part of maintenance treatment.			3,000		
Assouline, Sarit	Aegera Therapeutics Inc.	CRU - AEG35156-204: a phase 1-2, multicenter, open-label study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in patients with relapsed or refractory chronic lymphocytic leukemia, and indolent B cell lymphomas.			3,000		
Assouline, Sarit	Proteolix	CRU - PX-171-003 - An open-label, single-arm, phase 2 study of Carfilzomib in patients with relapsed and refractory Multiple Myeloma.			3,016		
Assouline, Sarit	Celgene Corporation				3,674		
Assouline, Sarit	Proteolix				4,014		
Assouline, Sarit	Glaxo Smith Kline	CRU - A three-part study of Eltrombopag in thrombocytopenic subjects with myelodysplastic syndromes or acute myeloid leukemia (part 1: open label, part 2: randomized, double-blind, part 3: extension).			5,000		
Assouline, Sarit	Glaxo Smith Kline	An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag study.			7,784		
Assouline, Sarit	Hoffmann-La Roche Limitée, Canada	CRU - BO21003 - An open-label, multi-centre, dose escalating, phase I/II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.			16,340		
Assouline, Sarit	Methylgene Inc.	CRU - A phase II study of MGCD0103 given three-times weekly in patients with relapsed and refractory lymphoma.			16,740		
Assouline, Sarit	Genzyme Corp.	CRU - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher Disease Type 1.			18,732		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Assouline, Sarit	Novartis Pharma Canada Inc.	CRU - A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at least two prior therapies.			19,182		
Assouline, Sarit	Hôpital Maisonneuve Rosemont	A prospective randomized phase II study evaluating the optimization of the residual plasmatic level of Dasatinib (Sprycel®) in patients newly diagnosed with chronic phase chronic myelogenous leukemia (CP-CML).			21,960		
Assouline, Sarit	Proteolix	CRU - An open-label, single-arm, phase 2 study of carfilzomib maintenance therapy in subjects previously enrolled in carfilzomib treatment protocols.			23,183		
Assouline, Sarit	Wyeth - Ayerst Canada Inc. (St-Laurent, Qc et North York, On)	CRU - A phase 1/2 study of SKI-6-6 in Philadelphia chromosome positive leukemias.			25,647		
Assouline, Sarit	Onyx Industries Inc.	CRU - A randomized, multicenter, phase 3 study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) vs. lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma.			29,275		
Assouline, Sarit	Ariad Pharmaceuticals Inc.	CRU - A pivotal phase 2 trial of Ponatinib (AP24534) in patients with refractory chronic myeloid leukemia and ph+ acute lymphoblastic leukemia.			33,462		
Assouline, Sarit	Hoffmann-La Roche Limitée, Canada	CRU-An adaptive, comparative, randomized, parallel-group, multi-center, phase Ib study of subcutaneous (SD) rituximab versus intravenous rituximab both in combination with chemotherapy (fludarabine and cyclophosphamide), in patients with previously untreated...			39,800		
Assouline, Sarit	Hoffmann-La Roche Limitée, Canada	CRU-A multi-center, open-label, phase I study of single agent R7112 administered orally in patients with acute myelogenous leukemia (AML) acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML) in blast phase, or refractory chronic lymphocytic			53,700		
Assouline, Sarit	Genentech Inc.	CRU - An open-label, multicenter, phase I trial of the safety and pharmacokinetics of escalating doses of DCDS4501A in patients with relapsed or refractory B-cell non hodgkin's lymphoma and chronic lymphocytic leukemia.			69,900		
Assouline, Sarit	Genentech Inc.	CRU-An open-label, multicenter, randomized, phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + RO5072759 (GA101) in patients with rituximab-refractory, indolent non-hodgkin's lymphoma.			84,508		
Assouline, Sarit	Millennium Pharmaceuticals Inc (Cambridge, Ma, Usa)				86,847		
Assouline, Sarit	Novartis Pharma Canada Inc.	Q-CROQ-02 - A randomized phase II study of oral panobinostat (LBH1589) with or without rituximab (the "Study Drug") to treat relapsed or refractory B-cell non-Hodgkin lymphoma.			190,089		
Baron, Murray	Astrazeneca Ab (Sweden)	OSKIRA-3 A phase III, multi-centre, randomized, double-blind, placebo-controlled, parallel group study of two dosing regimens of Fostamatinib Disodium in rheumatoid arthritis patients with inadequate response to TNF-alpha antagonist.			500		
Baron, Murray	United Therapeutics Corporation				736		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Baron, Murray	United Therapeutics Corporation	DISTOL-1: Digital Ischemic Lesions in Scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebo-controlled, multicenter study.			2,482		
Baron, Murray	Abbott Laboratories	Real life evaluation of rheumatoid arthritis in Canadians taking HUMIRA.			2,700		
Baron, Murray	Amgen Canada Inc (Mississauga, Ont)	20070301 - CAnadian Methotrexate and Etanercept Outcome study: an open label randomized trial of etanercept and methotrexate versus etanercept alone in the treatment of rheumatoid arthritis CAMEO"			5,162		
Baron, Murray	Amgen Canada Inc (Mississauga, Ont)	A multicenter, open label study to describe the safety of daily subcutaneous injections of Anakinar (r-metHuIL-1ra) in patients with rheumatoid arthritis.			9,675		
Baron, Murray	Actelion Pharmaceuticals Canada Inc.	AC-052-510 - A two-stage prospective observational cohort study in scleroderma patients to evaluate screening tests and the incidence of plumonary arterial hypertension and pulmonary arterial hypertention and pulmonary hypertension.			10,093		
Baron, Murray	Hospital Mount Sinai				17,000		
Baron, Murray	Pfizer Canada Inc.	A phase 2A randomized double-blinded, placebo & active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (PF-00489791) for the treatment of vasospasm			26,267		
Batist, Gerald	Pfizer Canada Inc.	PF-046691502-Phospho-Nrf2 as a novel biomarker for identifying patients for PI3K-mTOR inhibition to achieve selective chemosensitization.			70,000		
Blostein, Mark	Boehringer Ingelheim (Canada) Ltd	Resource utilization associated with oral anticoagulant management (ROAM) in Canada: a multicentre, prospective study.			3,675		
Blostein, Mark	Sanofi-Aventis (Canada)	ENOXA_L_02260-VTE Registry - National, prospective, observational cohort study of venous thrombembolism management with the low molecular weight heparin, enoxaparin, in the outpatient setting in Canada.			11,300		
Blostein, Mark	Bristol-Myers Squibb Canada Inc.	A phase 3, active (Warfarin) controlled, randomized, double-blind, parallel-arm study to evaluate efficacy and safety of apixaban in preventing stroke and systemic embolism in patients with nonvalvular atrial fibrillation.			66,486		
Chertkow, Howard	Janssen Alzheimer Immunotherapy	A phase 3 extension, multicenter, double-blind, long term safety and tolerability treatment trial of bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimers's disease who participated in study ELN115727-301 or in study ELN115727-302.			9,854		
Cohen, Albert	Abbott Laboratories	M10-223 - A multicenter, open-label study of the human anti-TNF monoclonal antibody adalimumab to evaluate the long term safety and tolerability of repeated administration of adalimumab in subjects with ulcerative colitis.			1,599		
Cohen, Albert	Robarts Research Institute (Formerly John P. Robarts Research Institute)	A randomized double-blind, placebo-controlled study to investigate the efficacy and safety of GSK1605786A in the treatment of subjects with moderately to severly active crohn's disease.			3,874		
Cohen, Albert	Robarts Research Institute (Formerly John P. Robarts Research Institute)	An open-label extension study to assess the safety of GSK1605786A in subjects with Crohn's disease.			4,137		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Cohen, Albert	Robarts Research Institute (Formerly John P. Robarts Research Institute)	A 52 week randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of GSK1605786A in the maintenance of remission in subjects with Crohn's disease.			4,137		
Cohen, Albert	Pfizer Canada Inc.	CRU - A4021018 - Randomized, open-label, phase 3 trial of Erlotinib alone or in combination with CP-751,871 in patients with advanced non-small cell lung cancer of non-adenocarcinoma histology.			5,700		
Cohen, Albert	Laboratoires Abbott Ltée	A multicenter, randomized, double-blind, placebo-controlled study of the human anti-TNF monoclonal antibody adalimumab for the induction and maintenance of clinical remission in subjects with moderately to severly active ulcerative colitis. #M06-827			7,072		
Cohen, Albert	Quintiles Canada Inc.	A phase 3, randomized, placebo-controlled, blinded, multicenter, multiple dose study for the induction and maintenance of clinical response and remission with MLN0002 in patients with moderate to severe ulcerative colitis.			7,407		
Cohen, Albert	Quintiles Canada Inc.	A phase 3, randomized, placebo-controlled, blinded, multicenter study, of the induction and maintenance of clinical response and remission with MLN0002 in patients with moderate to severe Crohn's disease.			14,797		
Cohen, Albert	Abbott Laboratories	An open-label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's disease - CALM.			269,066		
Cohen, Victor	Pfizer Canada Inc.	CRU - A4021016 - Randomized, open label, phase III trial of CP-751,871 in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer.			2,000		
Cohen, Victor	Novartis Pharma Canada Inc.	CRU - A phase II, multi-center, open-label study of AU922 administered IV on a once-weekly schedule in patients with advanced non-small-cell lung cancer who have received at least two lines of prior chemotherapy.			14,094		
Cohen, Victor	Pfizer Canada Inc.	EML4-ALK mutated non-small cell lung cancer in a western population_ a clinicopathologic study.			14,457		
Cohen, Victor	Novartis Pharma Canada Inc.	CASA404A2302 - A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with advanced metastatic (stage IIIB/IV) non-small cell lung cancer (NSCLC).			14,457		
Cohen, Victor	Pharmaceutical Research Associates Inc.	A multi-center phase III randomized, double-blind placebo-controlled study of the cancer vaccine Stimuvax (L-BLP25 or BLP25 liposome vaccine) in non-small cell lung cancer (NSCLC) subjects with unresectable stage III disease.			24,111		
Eisenberg, Mark	Pfizer Canada Inc.	GA3041Z4-Evaluation of Varenicline-(Champix™) in smoking cessation for patients post-acute coronary syndrome (EVITA) trial.			149,825		
Greenaway, Christina	Agennix, Inc.	A phase 2/3 randomized, double-blind, placebo-controlled study of the safety and efficacy of Talactoferrin Alfa in patients with sever sepsis.			5,437		
Hilzenrat, Nir	Merck Frosst Canada Inc	Study P04257: Effect of Infliximab in Hepatitis-C Genotype 1 Naïve Patients with High TNF-alfa on the Efficacy of Pegylated Interferon-alfa2b/Ribavirin Therapy.			2,920		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Hilzenrat, Nir	Glaxo Wellcome Inc.	TPL108390 - Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (suite ds résumé)			3,279		
Hilzenrat, Nir	Novartis	Pharmacogenomic analysis of blood samples to identify host genomic profiles that segregate responders from non-responders following treatment with Peg-interferon and ribavirin in HCV-infected subjects (genotype 1).			14,075		
Hirsch, Andrew	Sunnybrook Health Sciences Centre (Toronto, On)	A randomized phase III study of standard treatment +/- enoxaparin in small cell lung cancer, RASTEN study Canadian part.			3,712		
Hirsch, Andrew	Sanofi-Aventis (Canada)	DIREG_C_04823 - CANTARISK - A prospective, non-interventional, cohort survey on VTE risk in patients receiving a new chemotherapy for cancer.			8,420		
Hirsch, Andrew	Gilead Sciences	AARTEMIS-PH: A phase 3, randomized, double-blind, placebo-controlled, multi-center, parallel-group study to evaluate the efficacy and safety of ambrisentan in subjects with idiopathic pulmonary fibrosis and pulmonary hypertension.			19,703		
Hirsch, Andrew	Bayer Canada Inc.	Study 11348-Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with chronic thromboembolic pulmonary hypertension (CTEPH).			25,322		
Hirsch, Andrew	Bayer Canada Inc.	Study no 11349 - Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with chronic thromboembolic pulmonary arterial hypertension.			32,628		
Hoffer, Leonard J.	Immunotec Recherche	Method development to measure plasma amino acids and reduced total cysteine.			8,196		
Kahn, Susan Rebecca	Aventis Pharma	A double-blind, placebo-controlled, parallel, multicenter study on extended VTE prophylaxis in acutely ill medical patients with prolonged immobilization.			1,977		
Kahn, Susan Rebecca	Lawson Health Research Institute	A prospective study of upper extremity deep vein thrombosis to determine the prevalence of post-thrombotic syndrome in patients managed with anticoagulation.			12,250		
Kahn, Susan Rebecca	Quintiles Canada Inc.	A phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of (LMW) Heparin/Edoxaban versus (LMW) Heparin/Warfarin in subjects with symptomatic deep-vein thrombosis and/or			23,276		
Kahn, Susan Rebecca	Boehringer Ingelheim (Canada) Ltd	1160.46 - A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous (suite ds résumé)			61,050		
Karaplis, Andrew C.	Amgen Canada Inc (Mississauga, Ont)	Prospective observational study to evaluate persistence with Prolia (denosumab) in postmenopausal women with osteoporosis in routine clinical practice.			8,635		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Kavan, Petr	Covance Inc.	A RANDOMIZED, DOUBLE BLIND, PLACEBOCONTROLLED, MULTICENTER PHASE III TRIAL OFBEVACIZUMABAND TEMOZOLOMIDE VERSUS PLACEBO,TEMOZOLOMIDE ANDRADIOOTHERAPY FOLLOWED BY PLACEBOAND TEMOZOLOMIDE INPATIENTSWITH NEWLY DIAGNOSED GLIOBLASTOMA.			1,317		
Kavan, Petr	Sanofi-Aventis (Canada)	Gemcitabine and Oxaliplatin with Concomitant Radiotherapy as Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer			2,473		
Kavan, Petr	Amgen Canada Inc (Mississauga, Ont)	A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Pegfilgrastim Administered to Subjects With Newly DX, Locally-Advanced or Metastatic Colorectal Cancer Treated With Bevacizumab and Either 5-Fluorouracil, Oxaliplatin, Leucovorin (Folfox) or			2,846		
Kavan, Petr	Oncozyme Pharma Inc.	A PHASE 1/11 CLINICAL STUDY USING PENTAMIDINE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER UNDERGOING STANDARD THERAPY			3,972		
Kavan, Petr	Novartis Pharma Canada Inc.	A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors			4,291		
Kavan, Petr	Sanofi-Aventis (Canada)	A Randomised Phase III Study of Capecitabine or 5-Fluorouracil-Based Regimen with or without Oxaliplatin as 2nd Line Treatment of Advanced or Metastatic Pancreatic Cancer in Patients Who Have received Gemcitabine-Based Chemotherapy			4,697		
Kavan, Petr	Sanofi-Aventis (Canada)	A Multicenter, Randomized Double-Blind Placebo-Controlled Phase III Study Assessing the Efficacy of Oral Glutamine in the Prevention of Oxaliplatin Inducted Neurotoxicity in Patients with Colorectal Cancer Treated with Oxaliplatin in Adjuvant of 1st ...			5,433		
Kavan, Petr	Sanofi-Aventis (Canada)	Gemcitabine and Oxaliplatin with Concomitant Radiotherapy as Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer			7,534		
Kavan, Petr	Covance Inc.	A RANDOMIZED, DOUBLE BLIND, PLACEBOCONTROLLED, MULTICENTER PHASE III TRIAL OFBEVACIZUMABAND TEMOZOLOMIDE VERSUS PLACEBO,TEMOZOLOMIDE ANDRADIOOTHERAPY FOLLOWED BY PLACEBOAND TEMOZOLOMIDE INPATIENTSWITH NEWLY DIAGNOSED GLIOBLASTOMA.			12,025		
Kavan, Petr	Oncozyme Pharma Inc.	A phase II clinical study using Pentamidine in patients with metastatic cancer undergoing standard chemotherapy (mFOLFOX6 or FOLFIRI) as second-line treatment.			12,040		
Kavan, Petr	Boehringer Ingelheim (Canada) Ltd	BIBW 2992 WITH OR WITHOUT DAILY TEMOZOLOMIDE IN THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMA			15,042		
Kavan, Petr	Merrimack Pharmaceuticals	Signaling Signature of Osteoclastogenesis			20,207		



NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Kavan, Petr	Enzon Inc	CRU - A phase 2 study of EZN-2208 (PEG-SN38) administered with or without Cetuximab in patients with metastatic colorectal Carcinoma (mCRC).			34,367		
Langleben, Adrian	Boston Biomedical Inc. (Bbi)	CRU - BBI608-101 - A phase I clinical study of BBI608 in adult patient with advanced solid tumour.			109,320		
Langleben, David	Gilead Sciences	A phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study of ciclesanin in subjects with pulmonary arterial hypertension.			504		
Langleben, David	Actelion Pharmaceuticals Canada Inc.	AC-065A303: Long-term single-arm open-label study, to assess the safety and tolerability of Act-293987 in patients with pulmonary arterial hypertension.			2,500		
Langleben, David	Glaxo Wellcome Inc.	AMB110094 - A post marketing observational surveillance programme for Ambrisentan (VOLT).			3,385		
Langleben, David	Actelion Pharmaceuticals Canada Inc.	A multicenter, double-blind placebo-controlled phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension.			7,205		
Langleben, David	Bayer Canada Inc.	Study 12934 - Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, or 2.5 mg tid) in patients with symptomatic pulmonary arterial hypertension.			47,235		
Langleben, David	Actelion Pharmaceuticals Canada Inc.	AC-066A301/EPITOME-2: A multicenter, single-arm, open-label, phase 3b study to assess the effects of switching from Flolan to ACT-385781A in patients with (PAH). AC-066A302/EPITOME-2 extension: An open-label extension of ACT-385781A.			70,087		
Langleben, David	Bayer (Canada) Inc.				93,691		
Lapointe, Bernard Joseph	Wex Pharmaceuticals Inc.	CRU-TEC-006-A multicentre, randomized, double-blind, placebo-controlled, parallel-design trial of the efficacy and safety of subcutaneous tetrodotoxin (Tectin TM) for moderate to severe inadequately controlled cancer-related pain.			31,559		
Lapointe, Bernard Joseph	Pfizer Canada Inc.	CRU - A randomized, double-blind, placebo-controlled study of a fixed dose of subcutaneous methylnatrexone in adults with advanced illness and opioid-induced constipation: Efficacy, safety, and additional health outcomes. Protocol: 3200K1-4000/B2541005			31,604		
Lau, Susie Kit Sze	Centre de Recherche du Centre Hospitalier de l'université de Montréal (Crchum)				18,896		
Michel, Caroline	Bayer Canada Inc.	Study 143-08 - A randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the hemodynamic effects of riociguat (BAY 63-2521) as well as study & kinetics in patients with pulmonary hypertension associated with left...			49,302		
Miller, Mark A.	Merck Frosst Canada Inc	V212-001 A phase III, double-blind, randomized, placebo-controlled, multicenter clinical trial to study the safety, tolerability, efficacy, and immunogenicity of V212 in recipients of autologous hematopoietic cell transplants (HCTs).			33,271		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Miller, Mark A.	Actelion Pharmaceuticals Canada Inc.	A multi-center, double-blind, randomized, active reference, parallel group study to evaluate the efficacy, safety and tolerability of a 10-day twice daily oral administration of 3 doses of ACT-179811 in subjects with Clostridium difficile infection (DSI)			38,037		
Miller, Mark A.	Covance Inc.	Prospective observational study of nosocomial Clostridium difficile toxin antibody concentrations, incidence, and recurrence.			55,828		
Miller, Mark A.	Cubist Pharmaceuticals, Inc.	A randomized, double-blinded, active-controlled, dose ranging study of CB-183,315 in patients with clostridium difficile infection (CDI).			56,550		
Miller, Wilson	Novartis Pharma Canada Inc.	CRU-A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with trastuzumab.			500		
Miller, Wilson	Glaxo Wellcome Inc.	CRU- LPT109747 - An exploratory, phase II trial to determine the association of lapatinib induced fluoropyrimidine gene changes with efficacy parameters of lapatinib and capecitabine in first line gastric cancer.			500		
Miller, Wilson	Pfizer Canada Inc.	CRU - A3671016 - A phase I dose escalation trial of CP-675,206 in combination with Gemcitabine in patients with chemotherapy-naïve metastatic pancreatic cancer.			750		
Miller, Wilson	Glaxo Smith Kline	CRU - EGF105485 - A randomized, double-blind, multicenter, placebo-controlled study of Adjuvant Lapatinib in women with early-stage ErbB2 overexpressing breast cancer.			1,474		
Miller, Wilson	Bristol-Myers Squibb Canada Inc.	CRU - CA184-024 - A multicenter, randomized, double-blind, two-arm, phase III study in patient with untreated stage III (unresectable) or stage IV melanoma receiving Dacarbazine Plus 10mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine with placebo.			2,264		
Miller, Wilson	Pfizer Canada Inc.	CRU-A6181037-A SU011248 expanded access protocol for patients with cytokine-refractory or cytokine-intolerant metastatic renal cell carcinoma who are ineligible for participation in other SU011248 prot. but may derive benefit from treatment with SU011248.			4,477		
Miller, Wilson	Biovex Ltd (Uk)	CRU - A randomized phase 3 clinical trial to evaluate the efficacy and safety of treatment with OncoVEXGM-CSF compared to subcutaneously administered GM-CSF in melanoma patients with unresectable stage IIIb, IIIc and VI disease.			4,798		
Miller, Wilson	Ym Biosciences Inc.	CRU - A phase II, open-label extension study evaluating the long-term safety, tolerability and efficacy of orally-administered CYT387 in primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (CCL09101E).			5,800		
Miller, Wilson	Ym Biosciences Inc.	CRU - A phase I/II, open-label, study evaluating twice-daily administration of CYT387 in primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis.			8,300		
Miller, Wilson	Novartis Canada Ltd	CRU - A study II study of oral LBH589 in adult patients with refractory cutaneous T-cell lymphoma.			11,824		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Miller, Wilson	Bayer (Canada) Inc.	CRU - A phase I, non-randomized open-label study to evaluate the effect of BAY 73-4506 (regorafenib) on probe substrates of CYP 2C9 (warfarin), 2C19 (omeprazole) and 3A4 (midazolam) in a cocktail approach (Group A) and on a probe substrate of CYP 2C8.			14,319		
Miller, Wilson	Glaxo Smith Kline	CRU - VEG108844 - A study of Pazopanib versus Sunitinib in the treatment of subjects with locally advanced and/or metastatic rena cell carcinoma.			18,688		
Miller, Wilson	Bayer Canada Inc.	CRU - A randomized, double-blind, placebo-controlled phase III study of regorafenib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy. (Study 14387).			20,953		
Miller, Wilson	Infinity Pharmaceuticals	CRU - A phase 1b/2 study evaluating IPI-926 in combination with Gemcitabine in patients with metastatic pancreatic cancer.			24,169		
Miller, Wilson	Pfizer Canada Inc.	CRU-A two-arm randomized open label phase 2 study of CP-751, 871 in combination with exemestane alone as a first line treatment for postmenopausal patients with hormone receptor positive advanced breast cancer.			27,490		
Miller, Wilson	Hoffmann-La Roche Limitée, Canada	CRU - A multi-center, open-label, first-in-human, phase I dose-escalation study of single agent RO5503781, a small molecule MDM2 antagonist, administered orally in patients with advanced malignancies, except leukemia. Protcol no NP27872.			38,000		
Miller, Wilson	Novartis Pharma Canada Inc.	CRU - A phase Lb open-label dose escalation study of MEK162 plus RAF265 in adult patients with advanced solid tumors harboring RAS or BRAFV622E mutations.			46,489		
Miller, Wilson	Infinity Pharmaceuticals	CRU - Phase 2 combination with gemcitabine in patients with metastatic pancreatic cancer.			48,583		
Miller, Wilson	Ym Biosciences Inc.	CRU-Phase I/II, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of orally-administered CYT387 in primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis.			87,552		
Miller, Wilson	Glaxo Smith Kline	BRF113929: A phase II open-label, two-cohort, multicentre study of GSK2118436 a a single agent in treatment naïve and previously treated subjects with BRAF mutation-positive metastatic melanoma of the brain.			102,385		
Miller, Wilson	Glaxo Smith Kline	CRU - BRF113683: a phase III randomized, ope-label study comparing GSK2118436 to DTIC in previously untreated subjects with BRAF mutation positive advanced (stage III) or metastatic (stage IV) melanoma.			157,995		
Palayew, Mark	Boehringer Ingelheim (Canada) Ltd	A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 ug and 5 ug Tiotropium Inhalation Solution delivered by the Respimat Inhaler with Tiotropium inhalation capsul			14,084		
Pollak, Michael	Oncogenex Technologies Inc.	OGX-011-07 - A pilot study evaluating the safety and feasibility of OGX-011 in combination with second-line chemotherapy in patients with hormone refractory prostate cancer.			2,235		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Pollak, Michael	Pfizer Canada Inc.	CRU-A4021011-A phase 2, randomized, non-comparative, two-arm open label, multiple-centre study of CP-751,871 in combination with Docetaxe/Prednisone in chemotherapy-Naïve (Arm A) and Docetaxe/Prednisone refractory (Arm B) patients (suite)			5,500		
Pollak, Michael	National Institutes of Health	The breast radiology evaluation and study of tissues ("BREAST") stamp.			8,263		
Pollak, Michael	Pfizer Inc. (Usa)				9,439		
Pollak, Michael	Teva Pharma Industries Cda	CRU - A randomized phase 3 comparing standard first-line Docetaxel/Prednisone to Docetaxe/Prednisone in combination with Custirsen (OGX-011) in men with metastatic castrate resistant prostate cancer.			26,120		
Pollak, Michael	National Institutes of Health	C-peptide, adipocytokine, and inflammatory biomarkers related to obesity and pancreatic cancer.			33,928		
Pollak, Michael	Pfizer Canada Inc.	Phase I safety and tolerability study of figitumumab combined with pegvisomant in patients with advanced solid tumors.			39,590		
Pollak, Michael	American Cancer Society	Measure C-peptide, leptin, adiponectin, high molecular weight adiponectin, and TFG-beta levels in blood samples collected from CPS-II participants who developed pancreatic cancer and a group of matched controls.			129,934		
Pollak, Michael	Novo Nordisk A/S (Danemark)	Murine models to study the effect of diabetes and diabetes treatments, including insulin analogues, on cancer behavior.			200,000		
Pollak, Michael	Regroupement de Particuliers	IGF and breast cancer.			271,535		
Schiffrin, Ernesto	Kao Corporation (Japan)	Research on vascular disesae in hypertension: Role of endothelin, PPARs and T-lymphocytes.			10,016		
Schiffrin, Ernesto	Novartis Pharmaceuticals Corporation	A double-blind, randomized, parallel design study to compare the effectiveness of Aliskiren versus Hydrochlorothizide in mild-to -moderate hypertensive type II diabetes mellitus patients in reversing the remodeling of resistance arterisand correcting ...			25,491		
Sheppard, Richard	New England Research Institutes (Neri) (Usa)	Treatment Of preserved cardiac function heart failure with an Aldosterone anTagonist (N01-HC-45207TOPCAT).			7,550		
Sheppard, Richard	Novartis Pharma Canada Inc.	CSPP100A2368 - A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the 6 moths efficacy and safety of aliskiren therapy on top of stardard therapy, on morbidity and mortality when intitiated early after hosp			13,750		
Small, David	Pharmaceutical Product Development, Ppd Inc.				15,575		
Tagalakis, Vicky	Pfizer Canada Inc.	Post-operative venous thromboembolism in patients with cancer: A population based cohort study (WS462014)			10,000		
Tagalakis, Vicky	Sanofi-Aventis (Canada)	Determining the timing of venous thromboembolism in the post-operative setting: a population-based cohort study.			29,354		
Tagalakis, Vicky	Eisai Research Institute	FRAG-A001-401 - Dalteparin sodium injection (FRAGMIN), multi-center, open label, single-arm, controlled long-term (52 weeks) study for understanding safety and efficacy in subjects with malignancies and symptomatic venous thromboembolism.			36,118		
Therrien, Judith	Hamilton Health Sciences	BAV - Beta-blockers and angiotensin receptor blockers in bicuspid aortic valve aortopahy.			5,500		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Trifiro, Mark A	Boehringer Ingelheim (Canada) Ltd	A phase III, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10mg and 25mg administered once daily) as add on to pre-existing antidiabetic therapy over 52 weeks in patients with type 2 diabetes mellitus			11,045		
Trifiro, Mark A	Genome Prairie	Total utilization flax genomics (TUFGEN).			30,000		
Trifiro, Mark A	Instituts de Recherche en Santé du Canada	Innovative approaches to functional characterization of the androgen receptor in prostate cancer.			116,923		
Vaitekunas, Susan	Hoffmann-La Roche Limitée, Canada	Multicenter, randomized, double-blind, placebo-controlled, parallel-group two year study to evaluate the effect of subcutaneous RO4909832 on cognition and function in prodromal Alzheimer's disease.			9,450		
Wainberg, Mark A.	Merck Sharp & Dohme Research Laboratory	Part 1: Impact of subtype-specific variability on hte effectiveness of integrase inhibitor.			224,304		
Wainberg, Mark A.	International Science and Technology Partnerships Canada (Istp)	Novel HIV integrase inhibitors.			400,000		
Zaharatos, Gerasimos	Dynavax Technologies Corporation				18,034		
<b>Clinical Research Awards</b>							
Agulnik J.	Department of Medicine, JGH	Utility of different non-surgical biopsies in the genetic profiling and cellular differentiation of non-small cell lung cancer (NSCLC)				4,000	
Assouline S.	Department of Medicine, JGH	Combination of imatinib and chlorambucil for the treatment of patients with relapsed chronic lymphocytic leukemia and Efficacy of ribavirin for the treatment of acuter myeloid leukemia subtypes M4 and M5				4,000	
Baron M.	Department of Medicine, JGH	Statins in scleroderma				4,000	
Blostein M.	Department of Medicine, JGH	1. TIPPS (Thrombophilia in Pregnancy Prophylaxis Study): A multicenter, multinational randomised control trial of prophylactic low molecular weight heparin (LMWH) in high risk pregnant thrombophilic women				4,000	
Blostein M.	Department of Medicine, JGH	2. A Phase 3, Active (Warfarin) Controlled, Randomized, Double-blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Atrial Fibrillation					
Blostein M.	Department of Medicine, JGH	3. A Double-blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)					
Greenaway C.	Department of Medicine, JGH	The Burden of Infectious Diseases in Immigrants and Refugees: Reviewing the Evidence				12,000	
Gyger, G.	Department of Medicine, JGH	Videocapillaroscopy in systemic sclerosis and inflammatory myopathy				12,000	
Hilzenrat, N.	Department of Medicine, JGH	Short Term Memory Defect in Hepatitis C Patients Treated with Interferon				12,000	
Kader T.	Department of Medicine, JGH	C-peptide levels and how they predict insulin response in type two diabetic patients who have failed oral agents				4,000	
Miller M	Department of Medicine, JGH	Household transmission of C. difficile				4,000	
Nessim, S.	Department of Medicine, JGH	The Relationship Between Peritoneal Transport Status and Vitamin D Deficiency Among Peritoneal Dialysis Patients				12,000	
Rudski L.	Department of Medicine, JGH	Echocardiography-based research on the right heart				4,000	

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Sakr, L.	Department of Medicine, JGH	Understanding Phenotypical Heterogeneity of Potentially Curable Non-Small Cell Lung Cancer Using Cluster Analysis				12,000	
Schweitzer M.	Department of Medicine, JGH	Atorvastatin treatment in abdominal aortic aneurysm (AAA)				4,000	
Tagalakis, V.	Department of Medicine, JGH	Epidemiology of venous thrombosis and pharmacoepidemiology				12,000	
Sheppard, R.	Department of Medicine, JGH	Dysfunction of stress response systems and adverse cardiac remodeling after myocardial infarction				12,000	
Elizov, M.	Department of Medicine, JGH	Mentorship in Clinical Medicine				12,000	
Dascal, A	Department of Medicine, JGH	Microbiome Replenishment Strategies to Treat and Protect against C. difficile				8,000	
Palayew, M.	Department of Medicine, JGH	The Airways Centre at the Jewish General Hospital: Aspects of care in COPD patients				8,000	
Roshdy, O.	Department of Medicine, JGH	Analysis of the direct growth inhibitory effect of ipilimumab on melanoma cells				8,000	
Szilagyi, A.	Department of Medicine, JGH	IBD Epidemiology: Relationships with Vitamin D and population lactase distributions				8,000	
Wyse, J.	Department of Medicine, JGH	The value of Botox-A in Acute Radiation Proctitis				8,000	
<b>TOTALS</b>			<b>23,906,008</b>	<b>2,392,057</b>	<b>4,996,075</b>	<b>168,000</b>	<b>1,300,350</b>